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Cisplatin is one of the most effective cancer medications currently available. 
However, it is seriously limited by patient toxicity and drug resistance. As such, 
there is a real need for altemative treatments. Some compounds of gold(l) have 
been found to be biologically active in various contexts, including in killing 
cancer cells. The metal centres gold(lIl) and rhodium(lI) are isoelectronic to the 
platinum(ll) centre in cisplatin, and some of their compounds have been shown 
to have biological activity. The aims of this work were to prepare pyridine-
containing complexes of the three metal centres gold(I), gold(llI) and rhodium(I), 
and assess these complexes for in vitro anti-cancer activity. 
Phenyl pyridine and ferrocenylpyridine complexation was achieved with all three 
metal centres described above. With gold(I), either a chloride or 
pentafluorophenyl counter-anion was used. The rhodium(l) complexes contained 
1,5-cyclooctadiene moieties linked to the metal centre via diene complexation, 
and a chloride counter-anion. Phenylpyridine complexes of gold(lIl) were 
achieved via standard reaction with tetrachloroaurate anion. However, the 
analogous ferrocenylpyridine complexes display unusually low stability and other 
unexpected physical properties, and are believed to be highly novel chloro-
bridged gold dimers. 
The 4-phenylpyridine complex of rhodium(l) was initially found to be active 
against cancer cells in vitro. It was, however, demonstrated that this activity was 
actually due to the breakdown product of this compound in DMSO. It was found 
that this breakdown product interacts with DNA, implying a similar mechanism of 
action to cisplatin. This is supported by the fact that a cisplatin-resistant cell line 
displays hjgh cross-resistance against this product. (4-Phenylpyridine)gold(l) 












Future work should include further studies on the ferrocenylpyridine complexes 
of gold(III). and the development of a more reliable preparation for the active 
rhodium(l) product. More detailed biological characterisation of the gold(l) 
compound found to be active in vitro would be valuable, including studies on its 
mechanism of action. The DNA-binding experiments applied to the rhodium(l) 
products could be improved further. Since the mechanism of action of these 
compounds is still not completely clear, future investigations might include 
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Chapter 1. Introduction 
; 
Chemistry and Biological activity of Clsplatin 
Oesophagea/cancer 
Oesophageal cancer represents a significant health problem worldwide, 
especially so in the so-called 'cancer belt' of Asia (1) and parts of Africa, 
including South Africa. The squamous cell carcinoma subtype is most common 
in these developing countries (2,3), and is associated with various 
environmental factors, including smoking, drinking of alcohol and consumption 
of Fusarium-contaminated maize (4). Infection with various strains of the human 
papilloma virus may also be a risk factor (5). Because the disease is largely 
asymptomatic in its earlier stages, diagnosis often occurs only at an advanced 
stage, resulting in a 5-year mortality rate exceeding 90 % in South Africa (2,6). 
Surgery resection of the oesophagus remains the preferred front-line treatment 
against oesophageal cancer, depending on the stage at which the disease is 
diagnosed. Preoperative chemotherapy, alone or combined with radiation 
treatment, has been shown to yield modest advances in survival over surgery 
alone. Moreover, chemoradiation is often the sole treatment available for bulky 
or otherwise inoperable tumours. All of the standard chemotherapies rely on the 
use of the platinum-based drug cisplatin, often used in conjunction with other 
compounds such as 5-fluorouracil and epirubicin (7-9). 
History of platinum based drugs 
The antiproliferative activity of cis-diamminedichloroplatinum(lI) (1), more 











Rosenberg and colleagues in 1965. This was, in fact, a fortuitous accident, as 
these researchers had been intending to investigate the effect of an electric field 
on these bacteria - the compound was produced via a reaction between solutes 
in the nutrient solution and the platinum electrode (10). They subsequently 
demonstrated its potential as an antitumour agent (11). Cisplatin subsequently 
started being applied in clinical trials in the early 1970's and was approved for 
use by the US Food and Drug Administration (FDA) in 1978 (12). Its success 
has been most pronounced in the treatment of urogenital cancers - while 
testicular cancer, for instance, was once almost invariably fatal, cure rates may 
now exceed of 80 % (13). 
Shortly after it was first introduced, the major limiting factor for cisplatin 
treatment was severe toxicity towards kidney and gastrointestinal tissue. This 
sparked an active research effort in developing an analogue of cisplatin that 
produced the same anti-tumour effect, but lacked this toxcity. The most notable 
outcome of this was carboplatin. This is characterised by a much slower 
pharmacokinetic profile than cisplatin (for reasons explained below), thus 
eliminating the short-term acute toxicity that produced the undesirable effects. 
On the other hand, this means that much higher doses are required to achieve 
similar effectiveness against cancer cells. Carboplatin was approved by the FDA 
for clinical use in 1989 (14). Together, cisplatin and carboplatin now constitute 


















Current research into platinum-based chemotherapies now centres on 
circumventing the innate or acquired resistance that some tumours display to 
cisplatin and carboplatin (more on this below). Oxaliplatin (Figure 2, A) is a more 
water-soluble variant of carboplatin, which retains activity against cancer cells 
with acquired resistance to cisplatin. Moreover, it has a broader spectrum of 
activity than cisplatin and carboplatin, proving valuable against colon cancers in 
combination therapy, for instance (15,16). Other developments include 
satraplatin (Figure 2, B), which is designed to an orally available drug with 
similar pharmacokinetic profile to carboplatin, and shows promise in this regard. 
The large methylpyridine ligand of picoplatin (Figure 2, C), is designed to 
provide steric hindrance around the metal centre, thereby preventing the thiol-
coupling reactions that represent one of the main routes of cisplatin resistance. 
Indeed, this compound has shown promising activity against both cisplatin-
sensitive and resistant cancers in vivo (17). 
c 
Figure 2. Specialised derivatives of cisplatin and carboplatin. 
Chemistry and biochemistry of cispiatin 
Cisplatin had originally been prepared in 1845 by Michel Peyrone, after whom it 
was named Peyrone's chloride. Its structure was subsequently deduced by 











(18). The complex is prepared by a straightforward addition of ammonia to a 
tetrachloroplatinate salt (19), The cis- isomer is favoured over the trans-isomer 
because platinum(lI) exhibits a marked trans effect, whereby a ligand is able to 
destabilise the ligand trans to itself. In this case, chloride produces a more 
pronounced trans effect than ammonia so, after the first ammonia molecule 
bonds to the metal centre, the second ammonia ligand is unlikely to displace the 
chloride trans to it, instead displacing one of the chlorides in the cis position. 
Selectivity can be improved further by replacing the chloride ligands with iodide, 
as these produce a stronger trans effect. The trans isomer can be produced, but 
only by complete replacement of all ligands by ammonia, then reintroduction of 
chloride (20). 
• .. 
Figure 3. Preparation of cis- and transplatin 
E. coli bacteria exposed to cisplatin grow in filamentous forms (21), and are 
more susceptible to lysis by bacteriophage A. (22). Both of these attributes are 
associated with DNA damage, implying that DNA is cisplatin's biological target. 
This hypothesis was later given support by studies showing that cisplatin 
prevented incorporation of radiolabelled nucleotides (23), suggesting inhibition 
of DNA synthesis. Furthermore, cisplatin co-isolates with DNA orders of 
magnitude more readily than it does with RNA and protein fractions 'from 











with far greater affinity to DNA than to other biological molecules (24). Finally, 
using synchrotron radiation-induced X-ray emission (SRIXE), the concentration 
of an element like platinum can be mapped within individual cells, and is 
revealed to localise to the nucleus (25). 
A B 
Reactive towards DNA 
Figure 4. A: Hydrolysis of cisplatin. B: Depiction of cisplatin-DNA diadduct. 
The available evidence suggests that cisplatin forms covalent adducts to purine 
bases on DNA, primarily guanine (26). If cisplatin is allowed to react with salmon 
sperm DNA, which is then thoroughly digested with nucleases, a mix of free 
nucleotides and nucleotide-cisplatin adducts is obtained. These products may 
be separated by chromatography and analysed by 1 H NMR. This experiment 
reveals that the majority of cisplatin is found in the form of intrastrand diadducts 
including adjacent guanine bases. Most of the remainder is found as intrastrand 
adenine-guanine diadducts (27) and intrastrand guanine diadducts where a 
single nucleotide separates the two guanine bases. Only a small fraction form 











In aqueous solution, the rate-limiting step in cisplatin complexation to DNA is 
'activation' via the hydrolysis of labile Pt-CI bonds (Figure 4, A). The kinetics of 
hydration are strongly dependent on the concentration of chloride ion in solution. 
Thus, in plasma ([Cr] ... 100 mM). cisplatin is relatively stable, whereas in the 
cytosol ([CI1 ... 20 mM) the half-life for hydrolytic scission of a given bond is 
approximately 2 hours (29). The positively charged complex resulting from 
hydrolysis reacts rapidly with nucleophilic atoms on DNA. most commonly N7 on 
guanine. Although the reactive species of both cisplatin and carboplatin are 
identical, Pt-O bonds are not as labile as Pt-CI bonds, meaning that carboplatin 
is hydrolysed far more slowly and possesses a different pharmacologic profile. 
as discussed above (30). 
Effects on RNA transcription 
DNA is involved in several metabolically important functions in the cell, and the 
disruption of any of these can potentially result in cell death. Because cisplatin 
forms adducts to DNA, a reasonable initial hypothesis is that it exerts its 
cytotoxic activity by inhibiting DNA replication. Indeed, both the bacterial Klenow 
fragment (31) and mammalian polymerase (32) halt progression at the site of 
these ad ducts. The formation of diadducts, as opposed to monoadducts, is 
necessary for this inhibition, and lesions on adjacent guanine bases are most 
effective in stalling polymerases (33). Cisplatin inhibits replication effectively at 
lower concentrations than the geometrical isomer transplatin, largely because it 
is stereochemically more able to form diadducts after initial monocomplexation 
(34). 
If inhibition of replication was responsible for the cytotoxity of cisplatin adducts 
on DNA, we would expect cell cycle experiments to demonstrate that S-phase 
arrest is correlated with cell death, as this is the phase of the cell cycle in which 











expected, that S-phase arrest does occur and that the degree of inhibition of 
DNA synthesis is proportional to cisplatin concentration in various cell lines. 
However, using cell lines of differing sensitivity to cisplatin, they demonstrated 
that the characteristic feature of sensitive lines was the formation of G2/M arrest 
in response to cisplatin treatment. Cisplatin resistant lines generally underwent 
S-phase arrest of equal magnitude to sensitive lines, but then did not proceed to 
G2/M arrest. Therefore, although cisplatin brings about both G2/M and S-phase 
arrest, only the former is correlated with cisplatin cytotoxicity. 
To account for this, the authors suggested that cisplatin toxicity is mediated by 
inhibition of RNA transcription, which would prevent the production of proteins 
necessary for passage into mitosis and so bring about G2/M arrest and eventual 
cell death. This hypothesis is supported by experiments demonstrating that RNA 
polymerases are unable to transcribe RNA from DNA reacted with cisplatin (38). 
To complicate matters, Cullinane et 81 (39) subsequently showed that RNA 
transcription from undamaged DNA could be inhibited simply by the introduction 
of a platinated plasmid into Hela cells. This suggests that cisplatin-DNA adducts 
need not be present on the template DNA to inhibit RNA transcription, but 
merely be present in the cell. This suggests that these adducts may exert their 
effect by sequestering factors required for normal transcription to take place -
termed the "hijack" theory. The crucial victims of this sequestration are believed 
to be protein factors common to both DNA repair mechanisms and the 
transcriptional machinery. For a comprehensive review of this theory, including 
proteins implicated to date, see Jamieson and Lippard (40). 
Effects on te/omeres 
Because of their dependence on RNA primers, DNA polymerases are unable to 
replicate the ends of linear DNA molecules, leading to loss of information. To 











terminate in regions of long tandem repeats, of sequence (TTAGGG}n. These 
regions, called telomeres, are degraded by approximately 50 bp with each cell 
division. The result of telomere depletion is that most cells will stop dividing and 
enter senescence after a certain number of divisions (41). Cancer cells, 
however, are able to replicate indefinitely. One factor accounting for this is that 
late-stage malignant cells abnormally express telomerase, an RNA-dependent 
DNA polymerase that is able to extend telomeres (42). Experiments in HeLa 
cells suggest that even a dose of cisplatin that is not immediately lethal can 
cause shortening of telomeres, potentially reversing cancer cells' abnormal 
replicative longevity. Indeed, cells treated at a low dose of cisplatin often do die 
after several divisions, although more work is necessary to link this conclusively 
to telomere depletion. The greater sensitivity of telomeres to cisplatin treatment 
can be accounted for by two factors. Firstly, telomeres have high guanine 
content and a highly complex secondary structure, rendering them vulnerable to 
disruption. Secondly, whereas coding sequence is normally replicated in early S-
phase, telomeres are generally only replicated in late S-phase, thereby 
rendering them more vulnerable to the S-phase block characteristic of cisplatin 
(43). 
Pro-apoptotic effects 
Sorenson and Eastman (44-46) believe that the final mechanism of death for 
cisplatin-treated cells is apoptosis. This is confirmed by the accumulation of 
"sub-G1" cellular debris observable in cell cycle experiments performed on 
populations of treated cells. The DNA of affected cells develops double-stranded 
DNA nicks, producing a "ladder" in an agarose gel electrophoresis experiment 
that is characteristic of apoptosis. Finally, Lu and Cederbaum (47) have noted 
that cells treated with cisplatin for some hours undergo activation of caspase-3, -












Apoptosis, also termed "programmed cell death", occurs in response to severe 
cellular damage, especially to DNA. The process is initiated by detection of this 
damage by monitoring proteins, activating a signalling cascade. The end result 
of this cascade is the activation of proteases called caspases, which both 
directly degrade and indirectly bring about the degradation of cellular 
components, including the chromosomes and cell membrane (48). There is 
some evidence linking DNA repair machinery to induction of apoptosis. The 
primary means of repair of cisplatin lesions on DNA is the nucleotide excision 
repair (NER) system. While NER knockouts tend to exhibit increased cisplatin 
sensitivity (49), cell lines deficient in the mismatch repair system, another 
mechanism of DNA repair, tend to display cisplatin resistance (50). It is believed 
that the mismatch repair system, while recognising cisplatin lesions on DNA, is 
not able to repair them correctly. Instead, it attempts to 'repair' nucleotides on 
the strand complementary to that affected. As the lesion remains intact, the 
complementary nucleotides are continually recognised and continually being 
replaced. It is hypothesised that this 'futile cycle' of DNA repair creates a signal 
that enhances apoptosis (51,52). In light of this, it is interesting that testicular 
and ovarian tissue both tend strongly to express MSH2, an important component 
of the mismatch repair pathway, and that cancers deriving from these tissues 
are most effectively treated by cisplatin (53). Testicular tumours are also 
unusual among cancers in that they often have normal p53, a protein central in 
apoptotic signalling, particularly in the case of DNA damage. One might naturally 
speculate, therefore, that the presence of p53 renders these cancers vulnerable 
to induction of apoptosis by cisplatin (54). 
Clinical limitations of cisplatin 
A major problem associated with cisplatin is intrinsic or acquired resistance. This 











effective for only a limited time. Another major concern linked to this is that of 
'cross-resistance', whereby cells acquire resistance to both cisplatin and 
structural or functional analogues of the drug. It is hoped that these problems 
can be circumvented by the creation of novel cisplatin analogues (55). 
Cells generally acquire resistance to cisplatin by one of three mechanisms. For 
a comprehensive review, see Kartalou and Essigmann (56). One mechanism of 
resistance is simply a reduction in the quantity of compound present in the 
cytoplasm, which is largely accomplished via decreased intake. The alterations 
undergone by cells to achieve this decreased intake remain incompletely 
understood, but several mechanisms are known. Cisplatin influx into cells is 
thought to be a process of passive diffusion, through the membrane or 
transmembrane protein channels or pores. Resistant cancer lines may have 
mutations in these channels that prevent efficient passage of cisplatin. Channels 
of this sort are often 'gated' by the electrical potential across the membrane, 
accounting for the observation that some cisplatin-resistant cell lines maintain 
hyperpolarisation across their membrane (57), 
In recent years, particular attention has been paid to the copper homeostasis 
system (58). In particular, it is now believed that one of the major influx routes 
for cisplatin is copper transporter-1 (CTR1), a transmembrane pore protein. Ctr1" 
,. mammalian cells are found to accumulate only around 35 % as much platinum 
as wild type cells when exposed to clinically relevant concentrations of cisplatin 
(59). Furthermore, exposure to potentially cytotoxic levels of either copper or 
cisplatin brings about rapid downregulation of CTR1 protein, via intemalisation 
and proteasome degradation (60). ATP-dependent efflux proteins associated 
with copper transport, including ATP7 A and ATP7B, are also associated with 
cisplatin resistance. Increased expression of these proteins is linked to 











Cisplatin may effectively be detoxified by coupling to cellular thiol peptides, the 
best understood of which is glutathione. Attachment to glutathione precludes the 
formation of adducts to DNA, diminishing toxicity. It has been demonstrated (62) 
that some cisplatin-resistant cancer cell lines overexpress glutathione. In 
addition to the initial detoxification, once cisplatin is conjugated to glutathione, 
the entire assemblage can be exported from the cell via an ATP-dependent 
pump that recognises glutathione (63). 
Because cisplatin exerts its cytotoxic activity by inflicting lesions on DNA, cells 
are able to eliminate this toxicity by Increasing their repair of these lesions. Thus 
cisplatin-resistant cell lines have been demonstrated to undergo more efficient 
DNA repair (64). The most important upregulated pathway is that of nucleotide 
excision repair (NER), whereby several bases on either side of the lesion are 
removed and replaced (65). Interestingly, constitutive deficiency in this pathway 
is now believed to be one of the major reasons why testicular cancer is so 
responsive to cisplatin therapy (66). As mentioned above, the mismatch repair 
pathway is unable to repair cisplatin lesions, but may contribute to their toxicity. 
Cancer cells therefore tend to lose this pathway as they develop cisplatin 
resistance (67). 
A major problem with cisplatin is severe toxicity, particularly nephrotoxicity (55) 
caused by the apoptotlc death of healthy cells (68,69). Although nephrotoxicity 
can be controlled by intravenous hydration and administration of diuretics (70). 
this still tends to be the limiting factor in successful treatment of patients (55). 
Cisplatin's effects on renal tissue are therefore the best studied. Apoptosis 
appears to be promoted in the renal tissue via multiple routes, including 
inhibition of protein synthesis (71), as well as damage to the mitochondria 
(72,73) and the Iysosomes (74). It has also been demonstrated that, in rat renal 
tissue, cisplatin treatment causes activation of the tumour necrosis factor family 











The worldwide success of cisplatin and, conversely, some of the problems 
associated with cisplatin treatment, have spurred a very active worldwide 
research effort into the biological properties of precious metals. Various other 
platinum compounds have been developed as potential therapeutics. For a 
review of platinum compounds designed to circumvent resistance, see Kelland 
et al (76). While problems with toxicity have been partially alleviated using 
analogues such as carboplatin (77), these variants often display cross-
resistance with cisplatin. In recent years, interest has grown in compounds 
based on other metal centres, as the opportunities for cross-resistance are more 
limited here. However, many of these compounds share sufficient chemical 
similarities with platinum(lI) to allow for biological activity. Complexes of Au (78), 
Ru (79). Pd, Ir (80) and Rh (81) have been tested, although very few have 
reached clinical trials and none have as yet been certified as drugs (80). 
Chemistry and Biological activity of Rhodium(I) 
Introduction to Rh(l) chemistry 
The most easily attainable oxidation state of rhodium is rhodium(III). However, 
the +1 oxidation state has garnered interest in recent years, largely due to its 
catalytic properties. The extremely successful Wilkinson's catalyst is centred on 
a rhodium(l) centre. Rhodium(I), like platinum(II), has a d8 electronic 
configuration, and its complexes are generally four-coordinate and square 
planar. All known isolable complexes of rhodium(l) contain at least one IT-
acceptor ligand, which stabilizes and prevents oxidation of the metal centre. The 
most common ligands seen in catalysts are tertiary phosphines. The relative 
bulk of these ligands tends to result in coordinative unsaturation via ligand 











Chatt and Venanzi (83,84) produced the first coordination compound of 
rhodium(l) with a diene, 1,5-cyclooactadiene, to produce a chloro-bridged dimer. 
In the same work, they describe bridge-splitting reactions of this dimer with 
phosphines and amines, including piperidine and 2,2'-bipyridine. Partenheimer 
and Hoy (85) describe the first such reaction with pyridine as a ligand. In the 
same year, Pannetier and coworkers (86,87) prepared various chloro(1,5-
cyclooctadiene)(amine)rhodium(l) compounds, where the amine included 
pyridine, vinyl pyridine and methylpyridines. They demonstrated that the 
cyclooctadine ligand may be displaced by carbon monoxide under atmospheric 
pressure, and carried out infrared studies. 
Recently, Ra.iput et al (88-90) report the preparation of a series of complexes of 
the type (1,5-cyclooctadiene)(chloro)(L)rhodium(l) with L a substituted pyridine. 
They place particular emphasis on ferrocenyl, phenyl and other aromatic 
systems as substituents on the pyridine ring. These investigators have 
demonstrated that these sorts of compounds display interesting voltammetric 
properties, due to their conjugated systems of double bonds. 
Rhodium(l) complexes in cancer therapy 
Most of the recent interest in rhodium as a potential anti-cancer compound has 
centred on the +2 oxidation state, usually found in dimeric form and in 
conjunction with bidendate carboxylate ligands (Figure 5). These compounds 
are found to be cytotoxic in vitro and to be effective at inhibiting tumour growth in 
a nude mouse model . Moreover, the biological effectiveness is found to 
correlate positively with the length of the carboxylate aliphatic chain, which is 
thought to be due to the increased ability of more hydrophobic compounds to 
cross the cell membrane (91,92). These complexes have been found to interact 
with human serum albumen (93) and, more importantly, with DNA (94,95) . 











presence or absence of crucial DNA repair enzyme made no difference to the 
effectiveness of the treatment. 
Giraldi et al (99) went on to show that compounds of this type are also useful in 
a mammalian system (the compounds referred to by letters A-F, hereafter 
signify those so denoted in Figure 6). These workers demonstrated that 0 and F 
inhibit tumour growth in murine models of Ehrlich ascites carcinoma. In vitro, the 
compounds markedly inhibited protein synthesis after 4 hours, with far lesser 
effect on RNA and DNA synthesis. This contrasts with the inhibition of DNA 
synthesis observed for compound A and for cisplatin, suggesting a different site 
of action. Under these conditions, even the most active rhodium compounds 
tested displayed lower activity than Pt(lI) complexes. The authors attributed this 
to the high lability of the Rh-CI bond compared to the Pt-CI bond and to the 
potential for Rh(l) to be oxidised to Rh(lII) under cellular conditions. 
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Giraldi at a/ (100,101) report that compound C possesses antitumour activity 
that compares favourably to that of cisplatin. This complex attained complete 
cures in a murine model of Ehrlich ascites carcinoma at comfortably sublethal 
doses and inhibited metastasis in a model of Lewis lung carcinoma (102). 
Moreover, they report that the rhodium compound was less toxic than cisplatin, 
as measured by lesser reduction of body weight in the treated mice and less 
histologically apparent damage to the kidney, intestinal mucosa and spleen. 
Interestingly, they explain this selectivity in the same way they account for the 
lack of efficacy in D and F, in terms of the instability of these compounds to 
oxidation. Because the cytoplasm of a cancer cell is more reducing than that of 
a normal cell, they speculate that the compounds remain in their cytotoxic form 
for longer in these malignant cells. By monomer incorporation experiments, C 
can be shown to impact primarily upon RNA synthesis (103,104). E and, to a 
lesser extent, B are also reported to display some activity, but less than that of 
C, suggesting that both the carboxylate anion and the form of the diene ligand 
are important for biological activity. This may be rationalised in terms of stability 
effects, as the cyclooactadiene bidentate ligand (A-C, F), as opposed to the 
norbornadiene ligand of E, stabilise the +1 oxidation state of the Rh atom. 
Similarly, Rh-O bonds are generally more stable than Rh-CI bonds, whereas 
bidentate ligands tend to be kinetically inert (105,106). 
The same group of investigators have also prepared a related series of 
, 
compounds with pyridine-based ligands (Figure 7) (107,108). These were found 
to be effective against a mouse model of MCa murine mammary carcinoma, and 
to inhibit metastasis of Lewis lung carcinoma. On the basis of histological 
observations of other tissues, the authors conclude that the reduction in 
metastasis is attributable to alterations induced in the primary tumour, rather 
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Figure 7. Rhodium(l) compounds with pyridine-based ligands and anticancer 
activity. 
Rajput et al (88), have recently found several neutral and charged complexes of 
1,5-cyclooctadiene stabilised rhodium(l) compounds with pyridine-based ligands 
to have in vitro activity approaching that of cisplatin. The most effective of these 
are shown in Figure 8. In this work, it was decided to explore the more compact 
neutral complexes in more detail. 














Chemistry and Biological Activity of Gold(l) 
Introduction to Gold(/) Chemistry 
Gold(O) has the electronic configuration [Xe]4f14Sd106s 1. The nuclear charge of 
gold is very large, exerting a strong force, and thus a powerful acceleration on 
the electronic orbitals. The result of this is relativistic alterations to the expected 
energy levels of these orbitals. In particular, the Sd orbital is destabilised 
(enlarged), whereas the 6s and (to a lesser extent) 6p orbitals are 
stabilised/contracted. This effect is responsible for the resistance of metallic gold 
to initial oxidation, as compared the other elements in the same row of the 
periodic table, copper and silver. However, once oxidised, gold is able to enter 
much higher oxidation states than these metals, due to the relatively small gap 
between the Sd and 6s orbitals (109). This accounts for the tendency of Au(I), in 
aqueous solution, to disproportionate according to the following equation (110): 
3Au(l) -+ 2Au + Au(lIl) 
Gold(l) has the closed shell electronic configuration [Xe]4f14Sd 1o, isoelectronic to 
that of Zinc(II). This species is most commonly found complexed to two ligands, 
with linear stereochemistry (110). However, trigonal planar three-coordination, 
and tetrahedral four-coordination are also known (111). In contrast, in copper 
and silver, the +1 oxidation state tends to form four-coordinate cluster 
compounds. This is because relativistic contraction of the 6s orbital causes the 
6s-6p to be considerably greater in gold than the equivalent gap in Cu and Ag. 
This energy gap favours sp hybridisation, and therefore two-coordinate linear 
stereochemistry (112). 
Gold(l) is a relatively "soft" metal ion, as we would predict from its large size and 











anions such as rand CN- than for the lighter halides (109). However, there is 
also a pattern of anti-symbiosis, whereby a soft ligand can destabilize the bond 
of another soft ligand trans to itself. Thus the ligand P(OPhh tends to favour 
thiocyanate bonding to gOld(l) via N, rather than through the softer S. If we 
ignore anti-symbiosis, the relative affinities of gold(l) towards various neutral 
ligands are as follows (110): 
Ph3PO < Me2S < pyridine < AsPh3 < NH3 « PPh3 - MeNC < PMePh2 < 
PMe2Ph 
for biologically important ligands (113): 
COO- «CI- < His(=N-) - Met-S-CH3 «CN- - PR3 « CysS-
and the halides (113): 
F« cr < B( < r 
We note that the most favoured neutral ligands are phosphines, accounting for 
the general preference for these ligands seen in the literature. We can also see 
that that pyridine is not a particularly favoured ligand. 
Linear complexes of gold(l) are susceptible to a "trans influence", whereby a 
ligand is able to destabilize the bond of the metal centre to the substituent trans 
to itself. The strength of this effect is thought to increase with the a-donor ability 
of the ligand. As successively stronger a-donors are used, the bond to the trans 
ligand assumes a successively more diffuse IT-bond character, and the 
measured bond length between it and the metal increases (110). Jones and 
Williams (114) have carried out measurements of this trans effect in the [CIAuL] 











pyridine, in particular, is a weak a-donor and strong IT-donor, as one might 
expect. Thus it exerts a weak trans effect relative to ligands such as phosphines. 
There have been numerous published examples of Au-C a-bonds. These are 
most commonly prepared by reaction of an organolithium or Grignard reagent 
with gold(l) halide. This gives, by displacement of the halide, [RAuL], where R is 
the organic group and L is usually a tertiary phosphine. R groups include alkyls, 
phenyls, pentahalophenyls, ferrocenyl and ,,1-bonded cyclopentadienyl (110). 
The pentafluorophenyl anion is commonly used as a counter-ion in gold(l) 
compounds. 
The first preparation of (pyridine)gold(l) chloride is recorded from 1930 (115), 
and similar products can now be synthesised relatively routinely (116). Barranco 
et a/ have prepared complexes of the type [(3-ferrocenylpyridine) Au(l) X], where 
X is CI or C6Fs, via displacement of tetrahydrothiophene by the aromatic 
nitrogen.( Figure 9, A) These are found to be air- and moisture-stable red solids 
that are not conductive in acetone solution (117). The same investigators has 
also prepared similar ferrocene-containing complexes with the ferrocene moiety 
attached to a pyrazole (118) or a pyridine group (119) via a linker. (Figure 9, B). 
In a similar vein, Aguado et al have prepared an unusual ,,3-M3 complex, with 
each nitrogen of a ferrocene·linked terpyridine moiety coordinating Au(I)(C6Fs). ( 
Figure 9, C) As there are multiple gold atoms in this complex, aurophilic 
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Figure 9. Reported gold(l) compounds with substituted pyridine ligands 
Medicinal use of gold(J) 
The most conspicuous medicinal application of gold at present is in antiarthritic 
drugs. These primarily take the form of gOld(l) thiolates and phosphines (see 
Figure 10). The first of these was aurothioglucose, followed shortly afterwards 
by other thiol-based drugs. All of these must be injected for clinical 
effectiveness. The only orally available drug in this class is auranofin, which has 
both a thiosugar and a phosphine moiety. The mechanism by which these 
compounds alleviate the disease condition remains uncertain, but anti-immune 
activity is thought to playa prominent role (113,121). Following on the success 
of auranofin, the literature on gold(l) compounds in treating cancer has centred 
on phosphine ligands. Auranofin itself has proved cytotoxic against Hela cells in 




















Figure 10. Gold(l) complexes used in anti-arthritis therapy 
36 
Two distinct classes of phosphine-gold(l) anticancer compounds are presently 
being investigated for anticancer activity, and have recently been reviewed by 
Bernand and Berners-Price (123). The first class, neutral linear two coordinate 
Au(l) complexes, (see Figure 11, A) includes auranofin (124), (EhP)AuCI and 
many other compounds (125,126). These are thought to exert activity by 
interfering with an important anti-oxidant system in mitochondria. The proper 
functioning of many thiol-contalning enzymes is compromised by oxidation with 
hydrogen peroxide formed as a by-product of respiration in the mitochondrion. 
The peptide thioredoxin itself is oxidized as it restores these oxidized proteins. 
This "redox buffer" is maintained by the enzyme thioredoxin reductase, which 
reduces thioredoxin at the expense of oxidation of NADPH to NADP+ + H+. 
Auranofin and related compounds have been shown to inhibit the action of 
thioredoxin reductase (127). This prevents the repair of mitochondrial enzymes 
damaged by oxidation. More importantly, an excess of the oxidized form of 












The second class of phosphine-gold(l) anticancer compounds includes 
complexes with bis-coordinate phosphine ligands. Figure 11, 8) These generally 
have tetrahedral geometry and are cationic. These complexes appear to induce 
membrane permeability in the inner mitochondrial membrane, which is a key 
step in apoptosis. However, in variants with high lipophilicity, this membrane 
permeabilisation appears to occur in all cell types, instead of preferentially in 
cancer cells. This effect may be responsible for the severe in vivo hepatotoxicity 
that has resulted in several promising compounds being abandoned in pre-
clinical trials. The authors of the review suggest that more hydrophilic variants 
may be more selective for cancer cells, resulting in more acceptable toxicity. In 
this vein, Caruso et al (129) report a hydrophilic neutral phosphine-gold(l) 
compound with good activity against a panel of cancer cell lines. Pillarsetty and 
co-workers report similar results for an ionic complex, and link cell death to G1 
cell cycle arrest (130). 
Amine-gold(l) complexes are relatively under-represented in the medicinal 
chemistry, most likely because of the relatively stability of these complexes 
compared to the phosphine analogues. However, some experiments on 
(pyridine)gold(l) chloride are reported by Mirabelli et al (131). The authors 
demonstrate that this compound is able to interact with DNA in a cell-free in vitro 
system, is able to produce singe-strand breaks in the DNA molecule, as 






















Figure 11. Some examples of gold(l) phosphine compounds with anticancer 
activity 
Chemistry and Biological Activity of Gold(l/I) 
Introduction to Go/d(lll) Chemistry 
The +3 oxidation state is dominant in gold chemistry, although very rare in 
copper and silver. This is accounted for by the relativistic destabilisation of the 
Sd orbitals, as described above. Gold(lIl) has electronic configuration 
[Xe]4f14Sd6, with all known complexes existing in the low-spin state. In addition 
to being isoelectronic to Pt(II), nearly a" gold(lIl) complexes also have four-
coordinate square-planar stereochemistry, although there have been reports of 












geometry. The former may be invoked as an intermediate state for ligand 
substitution in square planar complexes (110). Interestingly, as is often seen in 
square-planar geometry, gold(lll) complexes exhibit a marked trans-effect. This 
means strong a-donor ligands are able to labilise the bond trans to themselves 
(110,132). 
The oxidation of metallic gold to gold(lIl) is associated with a large redox 
potential, and the gold(lIl) species is only stable in an aqueous system at low 
pH. This explains why a strongly oxidising acid, aqua regia, is required to oxidize 
gold. The presence of ligands other than water reduces this redox potential 
Significantly. However, even with a hard chloride ligand, this potential is still of 
the order of 1.0 V. Gold(III), because of its relatively high charge, is a "harder" 
Lewis acid than gold(l). As such, it has a higher affinity for nitrogen donors. 
Complexation to such ligands can usually be achieved by simple displacement 
of chloride from the tetrachloroaurate anion (110). 
Pyridinetrichlorogold(lll) was first prepared in 1903 by Renz and, independently, 
by Franyois (133,134). The latter also prepared [(C5H5NhAuBr2]Br, by 
recrystallisation of pyridinetribromogold(lIl) from pyridine. This compound is 
soluble in ethanol, acetone and chloroform, but sparingly soluble in ether and 
insoluble in water (135). Catallini et al have carried out a series of kinetic studies 
on pyridinetrichlorogold(llI) and related complexes. They have found that the 
pyridine ligand of a gold(lII) complex is considerably more susceptible to 
substitution by anions than the analogous ligand in a Pt(ll) system. This may be 
accounted for by the greater charge of the gOld(lII) centre, which allows it to 
form five-coordinate transition states necessary for associative kinetics. 
Because this transition state has a significant ionic character, the uncharged 
amine is favoured as the leaving group instead of the chloride ions (136). They 
have also determined that more basic ligands have more rapid kinetics of 
complex formation with gold(lIl) (137). Similar effects are observed for the 











(138). By the same token, it is observed that rate of displacement of pyridine-
based ligands also varies positively with basicity (139-141). These effects are 
also observed with platinum(II), but make far less difference to the reaction 
kinetics. These authors note, however, that steric hindrance plays a far more 
significant role in gold(lIl) compared to platinum(II), particularly in the case of 
relatively bulky thioether ligands (142). 
Aurocycle complexes including pyridine 
Metallocycles with pyridine N-donation have been prepared extensively, often 
with a view to exploring their photochemical properties (143). The most common 
approach to this is either via aliphatic amines that are substituents of the pyridyl 
moiety (144), or via bipyridal ligands (137). While bidentate N,N-donor ligands 
are more frequently seen in the literature, varieties of C,N-donor aurocycles 
have also been prepared. Vicente et al prepared 2-
[(dimethylamino)methyl]phenylgold(lII) in 1984 (145), while Parish and 
coworkers have prepared a variety of analogues (146). 
Constable and coworkers have used several analogues of 2,2'-bipyridine in the 
preparation of metallocycles, with a variety of metal centres (see (147-149)). In a 
particularly interesting work, they have demonstrated "roll-over" cycloauration of 
2-phenylpyridine (150). Parish et al (151) have shown that, while these 
complexes can be prepared by direct reaction of ligand with the 
tetrachloroaurate anion, transmetallation of [{Hg(2-phenylpyridine)CI}n] with 
tetrachloroaurate gives greater yields. In this work, they also confirm that a soft 
donor atom will tend to displace chloride trans to the heteroaromatic nitrogen in 
these complexes, as expected by the trans-effect. Che and coworkers have 
extended this transmetallation methodology to form C,C,N-donor chelates of 
gold with 2,6-diphenylpyridine (152). Fuchita et al have prepared analogous six-











Fuchita and coworkers have also prepared several imidazole (157) and 
thiophene (158) analogues of these complexes. Various poly-N-donor 
terpyridine complexes have also been described (159). 
Medicinal uses of gold(lll) 
Because of their similarity to platinum(lI) complexes, compounds of gold(lIl) 
might be expected to possess utility as anti-cancer drugs. Nevertheless, interest 
in this field has grown only recently. A review from 1994 (113) refers to gold(lll) 
primarily in the context of toxic side-effects of gold(l) drug compounds! A further 
problem is that many gold(llI) complexes are unstable under biological 
conditions, mainly due to reduction to metallic gold (160). 
Parish and colleagues have prepared various compounds of gold(llI) with a view 
to biological testing (161). In their more recent publications, these workers 
recommend the use of soft carbon-donor ligands, especially aromatic groups, in 
order to stabilize the metal centre against reduction. They report that one of 
these compounds (Figure 12, A) displays good cytotoxic activity against various 
cell lines in vitro, but that studies on xenograft mouse models are disappointing. 
possibly due to the low aqueous solubility of the compound (162). They note 
significantly improved in vivo activity with a more water soluble analogue 
(Figure 12, B). Using a gel electrophoresis mobility study, this compound was 
demonstrated to interact with DNA, but only minor effects were noted on the cell 
cycle (163). 
Henderson et al have prepared various 5- and 6-member aurocycles, using 
chloro, acetate and thiosalicylate anions (Figure 12, e), and observed modest 
anti-'cancer activity in some of the resulting compounds (164). They have also 
prepared complexes with catecholates (165) and imidates (166). Several of 











leukaemia cell line, although poor solubility is a problem with some of these 
compounds. 
A B c 
Figure 12. Aurocycle complexes of gold(lll) with antitumour activity. 
Messori and coworkers report the preparation of (2-
pyridylmethanol)trichlorogold(lII) and the N,O-donor aurocycle of this compound 
(Figure 13, A). They note that these compounds have poor solubility in water, 
potentially complicating their utility as biological agents. However, they are found 
to bind strongly to protein and DNA, and are reasonably cytotoxic towards 
cancer cells in vitro, although not as powerful as cisplatin (167). The same group 
have also reported that chloro glycylhistidinate gOld(lIl) is considerably more 
cytotoxic than its analogues containing platinum(II), palladium(II), zinc(lI) or 
cobalt(II), suggesting that the gOld(lII) centre is necessary for biological activity 
(168). They also note some cytotoxicity for bi- and tridentate nitrogen-donor 
ligands of gOld(lII) (169), although in this case the biological activity of the 
ligands in isolation was found to exceed that of the complex. However, Shi et al 
report that a 1,4,7-triazacyclononane complex of gold(lIl) shows cytotoxic 
activity comparable to cisplatin in vitro (Figure 13, B) (170) N,N- and C,N,N-
donor bipyridine based complexes gave more promising activity (Figure 13, C) 
(171,172). Most of these complexes, though not the bipyridine derivatives, were 











Messori et s/ have recently focused on these terdentate C,N,N-donor 
complexes. In particular, they have varied the anion at the fourth coordinating 
position, with a view to improving solubility and stability in aqueous medium. In 
general, these compounds were found to be stable for several hours under 
physiological conditions, and to exhibit reasonable toxicity against some cancer 
cell lines. As before the most active compounds were found to possess acetate 
cations (Figure 13, D) (173). These compounds were found to exert cytotoxic 
effect via apoptosis, as verified by cell cycle and TUNEL assays (174). 
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Figure 13. Some cytotoxic complexes of gOld(lll) 
Sun and coworkers have recently done some interesting work on gOld(lII) 
porphyrins. Some tetraarylporphyrin complexes were shown to have significantly 
greater activity against cancer cells than cisplatin, and to exert this activity 











coworkers may shed some light on these results. These latter investigators have 
demonstrated that the gold(llI)tetrakis(4-N-methylpyridyl)porphine is able 
efficiently to intercalate into DNA in vitro, and localizes to the nucleus in living 
cells (176). 
Objectives of this work 
The primary aim of this project is to identify precious metal compounds with 
promising anticancer activity, focussing on three metal centres - gold(l), gold(llI) 
and rhodium(l). Gold(lII) and rhodium(l) are chemically similar to platinum(lI) 
introducing the possibility that they may exert comparable biological activity, 
while avoiding some of the problems associated with cisplatin treatment. 
Additionally, unlike say paliadium(lI) (177), the biological properties of these 
species have not yet been thoroughly investigated, meaning that there is scope 
for novel discoveries. Gold(l) is already known to have biological activity (113). 
although by a different route to cisplatin (123), and may therefore serve as a 
useful contrast to the other metal centres. 
In this work, the decision was made to focus primarily on pyridine-based ligands, 
as opposed to phosphines, thiols, or any of the many organic ligands available. 
There were several reasons for this. Firstly, this work largely follows on from the 
results of Rajput at 8/ (88-90). wherein certain pyridine-based complexes of 
rhodium(l) were found to be biologically active against oesophageal cancer cells 
in vitro. Secondly, although complexes of platinum(lI) containing pyridine ligands 
are, due to their close similarity to cisplatin, fairly well-represented in the 
literature (178) pyridine complexes with other metal centres are rare. This is 
even the case where (as in this study) many of these ligands are quite readily 
available commercially or by simple synthesis. Therefore, from a chemical point 
of view. there is a certain interest in preparing and characterising such novel 











pyridine-based ligands are less intrinsically toxic, meaning they are easier to 
work with in a laboratory setting. This also means that any observed toxicity of 
the resulting complex may readily be attributed primarily to the metal centre, 
rather than the ligand. The complexes to be studied are depicted in Figure 14. 
Ar = aromatic group; A = anion; X = substituent 
Figure 14. Generalised structure diagrams for the complexes studied in this 
work. 
Successfully prepared complexes are to be characterised by standard methods, 
including nuclear magnetic resonance (NMR), elemental analysis, melting point 
analysis (m.p.) and UV-Visible spectroscopy. Biological activity is to be 
investigated via several methods. The most basic criterion against which to 
judge the value of potential anticancer drugs is cytotoxiC activity with respect to 
cancer cells. This can be evaluated against oesophageal cancers cells grown in 
vitro, using several well-understood methods. 
Since there is little value in compounds that are simply indiscriminately toxic 
towards human cells, more insight must be gained into the mechanism of action 
of these compounds. Firstly, the cytotoxic activity of test compounds on cancer-
derived versus relatively normal cell lines can be compared. This gives some 
idea of the therapeutic index, or selectivity, of potential drugs. There are several 
techniques that may be used further to probe the mechanism of cytotoxicity. 
Since cisplatin is known to exert activity via covalent attachment to DNA, several 











changes induced in the DNA molecule by the attachment of treatment 
compounds, using measures such as gel migration and circular dichroism. 
In summary, the complexes to be prepared include: 
• gold(I); 
• gold(III); and 
• rhodium(l) 
complexes with pyridine based ligands. 
These compounds are then to be characterised via: 
• NMR; 
• Elemental analysis; 
• UV-Vis spectroscopy; 
• Cytotoxicity studies; 











Chapter 2. Synthesis and characterisation of ligands and complexes 
Results and Discussion 
Preparation of ligands 
Preparation of ferroceny/pyridine ligands 
The preparation of these ligands was attempted, at least in the first instance, by 
reaction of the diazonium salt of the appropriate aminopyridine with ferrocene. 
Unfortunately. however, it soon emerged that this technique was only 
appropriate for the 3-isomer. This is a consequence of the relative lability of 
different isomers of the diazonium reagent. The diazonium salt of 3-
aminopyridine reacts via a relatively slow SN2 pathway. In contrast, the 
corresponding dlazonium salts of 2- and 4-aminopyridine are able to undergo 
rapid SN 1 loss of nitrogen gas. (Figure 15) This is possible because the loss of 
the diazonium moiety results in a carbocation that is stabilised by resonance 
donation of electrons from the nitrogen, whereas the equivalent 3-isomer would 
not be so stabilised. Therefore, the 2- and 4-isomers are able to react rapidly via 
the SN 1 pathway, often taking up chloride ions present in the hydrochloric acid 
solution in which diazonium salts are usually prepared (180). 
o· CI 
Figure 15. Spontaneous decomposition of the diazonium salt of 2-











The reaction of ferrocene with the diazonium salt of 3-aminopyridine was 
attempted via a phase-transfer methodology (181). However, it was found that 
several side-products were formed and that yields were generally low, resulting 
in a large excess of starting material in the reaction mixture. Because of this, 
pure product could not be readily obtained, even by column chromatography. 
Therefore, a more "old-fashioned" technique (182), exploiting the mutual 
solubility of the diazonium salt and ferrocene in glacial acetic acid, was 
employed. (Figure 16) After extensive diethyl ether extraction of the resulting 
product mixture, more than 2 g of 3-ferrocenylpyridine was obtained. 
1 
Figure 16. Diazonium preparation of 3-ferrocenylpyridine 
An organolithium technique (183) was employed in the preparation of 2-
ferrocenylpyridine (Figure 17). As with the diazonium technique, this preparation 
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Attempted preparation of (4'-methoxypheny/)pyridine 
This ligand was targeted with the intention of creating bulkier and slightly more 
hydrophilic analogues of the phenyl pyridine ligands used extensively in this 
work. One attractive feature of these compounds is that there is an established 
method (184) of preparing them via diazonium chemistry, the techniques for 
which were already well-known to the author because of their use in the 
preparation of 3-ferrocenylpyridine. Moreover, a relatively recent publication 
describes the simple separation of the various isomers produced via column 
chromatography (185). However, although fractions enriched in one-or-other 
isomer were easily obtained, no completely pure isomer was successfully 
isolated by chromatography. 
\ 
[ ~l N-N · '00- + o N • C{ u 
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(separate isomers by column) 
Figure 18. Attempted preparation of (4'-methoxyphenyl)pyridine , via diazonium 
chemistry 
Preparation of metal complexes 
Preparation of go/d(l) complexes 
In this work, several linear complexes of gold(l) have been prepared. This metal 
centre is usually accessed via the reduction of a gOld(lII) species with a thioether 











tetrahydrothiophene gOld(l) chloride from auric acid (Figure 19. A). The 
tetrahydrothiophene gOld(l) pentafluorophenyl starting material is obtained from 
this compound via anion replacement, using an organolithium reagent. (Figure 
19. B) Following the protocol of Barranco et al (117). (3-
ferrocenylpyridine)gold(l) chloride has been prepared. although in somewhat low 
yield, most likely due simply to the small scale on which the reaction was 

















Figure 19. Preparation of (THT)gold(l) chloride (A) and (THT)gold(l) 
pentafluorophenyl (B) 
Despite following this method closely. the preparation of the corresponding 
phenyl pyridine complexes has been considerably more difficult. This is most 
likely because of the preference of the gold(l) centre for "softer" ligands, as 
noted above. Whereas the ferrocenyl substituent of ferrocenylpyridine is 











leading to increased electron density on the pyridine nitrogen. Thus the metal 
centre is presented with a "hard" ligand which contributes to instability. 
As noted in the introduction, above, gold(l) species readily disproportionate into 
gOld(lll) and metallic gold. Unfortunately this problem of stability has been a very 
significant challenge in preparing pure phenylpyridine gold complexes. These 
products are unstable in those solvents in which they are soluble, presumably 
because the disproportionation takes place more readily if the molecules of the 
complex are able to come into contact with each other, as in solution. While a 
more detailed study of the stability of these complexes in various solvents is 
outside the scope of this study, it is worth noting that the process of 
disproportionation was more rapid in more polar solvents. Hence colloidal gold is 
formed virtually instantaneously upon contact with acetone or DMSO, and over 
the course of a few minutes in chloroform. Nevertheless, if care is taken, these 
complexes do exist in chloroform for long enough to acquire NMR spectra. 
In dichloromethane, by way of contrast, colloidal gold is not observed to 
preCipitate for several hours. Thus this has been the preferred solvent for 
complex formation. Nonetheless, each reaction must be timed carefully to avoid 
decompOSition. Also, after the reaction is complete, the solvent must be 
removed in vacuo and the product washed with diethyl ether and then 
thoroughly dried. Two of the three potential isomers of (phenylpyridine)gold(l) 
chloride have been prepared in this way, and been satisfactorily characterised. 
With knowledge of the literature, some attempt can be made to rationalise the 
differing stability of the various complexes. It is known that the gold(l) centre, in 
general, has greater affinity for "softer" electron donors. Since the ferrocene 
moiety of ferrocenylpyridine is expected to be a net acceptor of electron denSity, 
we expect the pyridine nitrogen of this ligand to be a considerably weaker 
electron donor than the corresponding nitrogen of phenylpyridine, where the 
benzene moiety contributes to increased electron density. This accounts for the 











thus, their presence in the existing literature), and the corresponding instability 
of phenylpyridine complexes. 
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Figure 20. Preparation of pyridine based complexes with gOld(l) chloride 
(Phenylpyridine)gold(l) pentafluorophenyl complexes generally exhibit greater 
stability in solution, forming a fine purple precipitate of colloidal gold only after 
some hours in chloroform. Each of the three potential isomers of this compound 
has therefore been prepared in high purity (Figure 21). The yield for each of 
these preparations remains low (approximately 10-50 %), partially because of 
the small scale, but also because these complexes are slightly soluble in diethyl 
ether, resulting in material being lost during the washing phase. Better yields 
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Figure 21. Preparation of pyridine based complexes with gOld(l) 
pentafluorophenyl 
Preparation of goldOIl) complexes 
Gold in the 3+ oxidation state is obtained by the oxidising effect of aqua regia, a 
mixture of nitric and hydrochloric acid known by mediaeval alchemists to 
dissolve gold. (110) The product of this oxidation is auric acid, which is easily 
converted to sodium tetrachloroaurate. (Figure 22) Both of these species are 
here used as starting materials. The first preparation of (pyridine)gold(lII) 
. trichloride is dated to the beginning of the twentieth century, so the chemistry of 
this sort of compound is relatively well-understood. The method of Colles and 
Gibson (135), dating to 1931, has been used in preparing this compound. 
(Figure 23) This method gives a product in good yield, and with characterisation 
data matching expectations. However, for the phenylpyridine complexes of 
gold(III), it was decided to use the experimental conditions cited for the 
preparation of (2-phenylpyridine)gold(lII) trichloride by Constable and Leese 
(186). This method gave pure yields generally in excess of 70 %. (Figure 24) A 
complete set of geometric isomers of (phenylpyridine)gold(lIl) trichloride was 
prepared via this method. The cycloaurated compound (2-











25), as transmetallation techniques were felt to be unnecessarily complicated 
and hazardous. 
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Figure 23. Preparation of (pyridine)gold(llI) trichloride 
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Figure 25. Preparation of (2-phenylpyridine)gold(lIl) dichloride 
55 
+ HCI 
Hijazi et al (187) present a very intriguing piece of work. By simple reflux of a 
ruthenium starting material with a 2-phenylpyridine derivative, they are able to 
form a C,N-donor ruthenocycle. This methodology follows directly from the 
syntheses described above. However, they then go on to carry out the 
analogous reaction with 2-ferrrocenylpyridine, yielding a C,N-ruthenocycle with 
ferrocene in the ring. This work suggests that it might be stereochemically 
feasible to form an analogous 2-ferrocenylpyridine aurocycle, although no 
precedent exists for this in the literature. Ferrocene carbon-gold a-bonds have 
been demonstrated, but only via lithiation of ferrocene to form a strong 
nucleophile (188,189). 




















Following the protocol taken from Constable and Leese, preparation of the 2-
ferrocenylpyridlne aurocycle first requires the N-donor complexation of the 
pyridine moiety. Ferrocenylpyridine analogues of the phenylpyridine complexes 
were thus attempted via this protocol, yielding bright green solids, in contrast to 
the shades of yellow usually encountered with complexes of gold(III). 
Interestingly, and in strong contrast to the phenylpyridines, it was found that 
these complexes were characterised by marked instability. These compounds 
appeared to break down very rapidly into colloidal gold in solution, and rather 
more slowly in aqueous suspension. Moreover, it was found that addition of 
excess ligand during complex formation similarly resulted in the formation of a 
fine black precipitate consistent with colloidal gold. This response was similarly 
elicited when ferrocenylpyridine was added to the gOld(lII) starting material in 
solution of acetonitrile, as was done with phenyl pyridine, presumably due to 
excess local concentration that may occur in even a well-stirred mixture. This 
necessitated that solid ferrocenylpyridine be added directly to an aqueous 
solution of tetrachloroaurate ion, resulting in a relatively slow reaction yielding 
apparently pure product. 
This problem of instability meant that the cycloaurated complex of 2-
ferrocenylpyridine was unlikely to be achieved, although a transmetallation 
methodology may overcome this difficulty. Nevertheless, the unexpected 
properties of the green complexes represented an interesting problem in itself. 
Because of the instability of these products, isolation and characterisation 
represented a significant challenge. However, elemental analysis was performed 
successfully in the case of the 3-ferrocenylpyridine isomer. The same analysis 
was not performed for the 2-ferrocenylpyridine isomer but, Since It is similar to 
the product under discussion, in both appearance and the physical properties 
noted above, it is reasonable to assume that following discussion will apply here 
also. Despite the apparent purity of the 3-ferrocenylpyridine product, as 
assessed by the colour and texture of the solid, this analysis did not yield data 











27, A). These data were, however, consistent with the formula (3-
ferrocenylpyridne)gold(lIl) dichloride tetrachloroaurate. Since gold in the 3+ 
oxidation state is generally found to have 4-coordinate geometry, this formula 
would necessitate the formation of a chloro-bridged gold dimer, as depicted in 
Figure 27, B, below. This sort of structure is known in the literature 
(158,190,191), usually in the context where the incoming ligand is an anion. 
However, given the lack of further rigorous analytical data supporting this 
structure, it must remain a tentative proposal. Nevertheless, several pieces of 
observational evidence do support the hypothesis, as described below. 
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Figure 27. Original proposed structure for the gold(lII) complex of 3-
ferrocenylpyridine (A) and structure hypotheSised in the light of elemental 











Firstly, it should be noted that the physical properties of the product are 
substantially different to those of the corresponding phenylpyridines, including 
colour but especially its far greater instability. As noted above, this compound 
proved highly unstable in solution (of both non-halogenated organic polar 
solvents and chlorinated solvents). Moreover, the slow decomposition of the 
complex in aqueous suspension is markedly increased in contact with metal -
black decomposition product is observed to form on a metal spatula used in 
processing the reaction product, for instance. This last observation might lead to 
the conjecture that decomposition involves a redox reaction that is perhaps 
catalysed by the availability of free electrons in a metal. The second interesting 
observation is that the product is noticeably more stable in aqueous solution 
containing tetrachloroaurate ion than in pure water. This is clear from the way in 
which product that has been collected by filtration and washed by pure water 
decomposes much more rapidly than product from the same batch that has 
remained standing In the mother liquor. This suggests that the dissociation of 
tetrachloroaurate ion is a crucial step in decomposition, as it is this step that 
would be dlsfavoured by a high concentration of the ion in the surrounding 
medium. This may also account for the generally instability of the product in 
solution, especially with polar solvents, as these solvents are more likely to bring 
about ionic dissociation. 
Despite the Instability of the product in solution, an NMR spectrum (Figure 28) 
was recorded in deuterated acetone, the solvent in which visible decomposition 
appeared to be slowest. The only peaks of interest were of very small magnitude 
and were quite broad, occurring at 9.23 and 8.43 ppm. Despite the poor quality 
of these data, the position of these peaks is consistent with a pyridine moiety 
bonded to a strongly electron-withdrawing metal centre, as this tends to produce 
a downfield shift. For instance, the most downfield pyridine signal for 4-
phenylpyridine occurs at 8.66 ppm, whereas the corresponding signal for (4-
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Figure 28 1H NMR spectrum of the 3-ferrocenylpyridine complex of gold(III), 
recorded in acetone-d6 
Finally, an infrared spectrum was determined for the product (Figure 29). 
Altogether, the measured absorption peaks largely match those previously 
observed for 3-ferrocenylpyridine (88). However, the spectrum for 18 also 
contains a variety of signals at wave numbers of 355 cm-1 and lower, which are 
very likely due to Au-CI bonds. Following Adam and Churchill's (192) 
characterisation of the most basic chloro-bridged gold dimer, AU2Cls, we can 
assign these signals more specifically. The series of peaks in the 355-303 cm-1 
region correspond to the stretching mode of Au-CI bonds, for either terminal or 
bridging chlorides. Interestingly, the spectrum shown here has a distinct signal 
at 295 cm-1, which matches closely a 291 cm-1 signal assigned by these authors 
to a bridge stretching mode. This observation provides further support to the 
hypothesis that the reaction product of 3-ferrocenylpyridine with 
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Figure 29. IR spectrum for 18. (A) The complete spectrum; (8) a magnification 
of the 400-200 cm-1 region, containing the majority of peaks corresponding to 
Au-CI. 
The one other pyridine-based ligand used for these studies was 











by addition of solid ligand directly to an aqueous solution of tetrachloroaurate 
(Figure 30), this method being used mainly because the ligand was insoluble in 
acetonitrile and other water-miscible solvents. Complex-formation was observed 
in the gradual colour change of the precipitate from white to yellow, and the 
corresponding removal of colour from the supernatant. The relatively slow 
reaction time observed here, in comparison with phenylpyridine or 
ferrocenylpyridine was most probably due to the fact that this ligand has both an 
acidic hydroxyl moiety and basic pyridyl group, meaning that it is likely to form a 
zwittterion at neutral pH. Thus, at equilibrium, only a small proportion of ligand 
molecules will have the reactive pyridine nitrogen available for complexation. 
+ .. 
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Figure 30. Preparation of (hydroxy(phenylmethyl)-phenylpyridylmethane) 
gold(lll) trichloride 
Preparation of rhodium(/) complexes 
The basic st~rting material used for most reactions was the J..I-chloro(1,5-











straightforward to prepare, stable in air at room temperature, and easy to work 
with. The basic synthetic path for all pyridine N-donor complexes of Rh(l) follows 
the method suggested by Rajput (90) and Fougeroux et al (87), namely stirring 
the ligand with the dimeric starting material in dichloromethane. Most complexes 
were obtained in high purity, as assessed by NMR, and yields ranging from 40 -
80 %. Elemental analysis revealed (1,5-cyclooctadiene)(2-
ferrocenylpyridine)rhodium(l) chloride to be impure, in a fashion consistent with 
the presence of starting material in the product. This was most likely to the fact 
that the reaction was attempted on a small scale and with 1:1 stochiometry, a 
combination of factors that may have resulted in a small measurement error (Le. 
of the mass of ligand) having a relatively large effect on the product. The 
presence of starting material is also suggested by "shoulders" in the 1H NMR 
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Figure 32. Preparation of pyridine based rhodium(l) complexes 
Some reactions were also attempted with the chlorobis(cyclooctene)rhodium(l) 
dimeric starting material, which was prepared via an established literature 
method (193). (Figure 33) Although elemental analysis revealed that the starting 
material was somewhat impure, it was decided to react this dimer with pyridine 
and 4-phenylpyridine, yielding fine powders quite distinct in appearance from the 
dimer. The starting material and resulting products appear to be almost entirely 
insoluble in all organic solvents, so that reactions were carried out in toluene 
suspension with easy separation of products via filtration, as suggested by 
Milstein and co-workers (194,195). AlthoUgh lack of solubility disallowed NMR 
analysis of the starting material, the products of reaction with pyridine containing 
ligands were found to be very slightly soluble in chloroform. The NMR spectra 
consequently obtained were found to contain peaks in the aromatic region, 
suggesting successful complexation with these ligands, although the peaks were 
too faint to allow reliable proton quantitation. The elemental analysis data 
obtained for these products were characterised by much lower carbon and 
hydrogen, and higher nitrogen, composition than would be expected if complex 
formation proceeded via a bridge-splitting reaction like that seen with the 1,5-










starting material, this type of reaction is outcompeted by displacement of the 
alkene by the N-donor ligands (see Figure 34). 
26 
Figure 33. Preparation of chlorobis(cyciooctene)rhodium(l) dimer 













General experimental conditions 
Syntheses were carried out in air, unless otherwise stated. Were oxygen-free 
conditions were required, syntheses were performed under prepurified nitrogen 
gas, using standard Schlenk techniques. Deionised water (dH20) was prepared 
by filtration through an ion exchange resin. All solvents were used as received, 
except where Schlenk techniques were applied, or otherwise indicated. Where 
necessary, diethyl ether was distilled under nitrogen from 
Na/benzophenone/tetraglyme prior to use, then stored under nitrogen (196). 
Ethanol and acetone (Merck) were used as received. 0.10 M HCI was obtained 
from Cameron Chemical Consultants, Clareinch, South Africa. All other reagents 
were obtained from Sigma-Aldrich and used as received, unless otherwise 
stated. Thin-layer chromatography was carried out on silica plates (Machery-
Nagel, 0.20 mm Alugram SIL G/UV254). Column chromatography was carried out 
using silica gel (Merck, Silica Gel 60). Melting point experiments were carried 
out on a Kofler hot-stage microscope (Reichert Thermovar), with the sample 
pressed between glass coverslips. Elemental analyses were conducted with a 
Carlo Erba EA 1108 apparatus. NMR spectra were obtained with either a Varian 
Unity-400 (H: 400 MHz; C: 100.6 MHz) or a Varian Mercury-300 (H: 300 
MHz; C: 75.5 MHz) spectrometer, both at the University of Cape Town. 
Infrared spectra were determined on a Perkin-Elmer Spectrum One FT-IF 
Spectrometer, with the sample prepared in a Nujol mull pressed between two 
sodium chloride plates. Each sample was scanned twelve times and the final 











Preparation of ligands 
Preparation of 3-pyridinylferrocene (1) 
This was prepared via a modification of a previously reported technique (197). 3-
Aminopyridine (4.706 g, 50 mmol) was dissolved in a mixture of dH20 and 
HClconc (1:1) (40 ml) and cooled in an ice bath. NaN02 (3.795 g, 55 mmol) in ice-
cold dH20 (20 ml) was added dropwise to this. This resulted in a colour change 
of the solution from pink to yellow, indicating the formation of the diazonium salt 
of 3-aminopyridine. The diazonium salt was then added slowly, with stirring, to 
ferrocene (9.302 g, 50 mmol) in glacial acetic acid (350 ml), at room 
temperature. Gas was observed to evolve from the reaction mixture, which was 
allowed to stir overnight. After completion of the reaction, the mixture was 
basified by addition of NaOH (0.10 M), which caused the preCipitation of solid 
material. The pH was monitored using Merck Universal Indicator strips. The 
preCipitate was collected by centrifugation (2000 rpm, 10 min) and the reddish 
supernatant discarded. Product was recovered from the precipitate by 
exhaustive diethyl ether extraction. The ether fractions were dried over MgS04, 
then removed by rotary evaporation. The product was then redissolved in 
minimal n-hexane. 3-Pyridinylferrocene was confirmed to be present in the 
sample by thin-layer chromatography (Rf = 0.55 in EhO). The solution was 
loaded onto a silica column (Merck, Silica Gel 60) and unreacted ferrocene 
eluted as an orange band with n-hexane. 3·Pyridinylferrocene was not mobile in 
n-hexane, but eluted as a deep red band upon addition of diethyl ether to the 
column. The collected fraction was dried with rotary evaporation to yield 3-
pyridinylferrocene as orange granules (2.263 g, 8.60 mmol, 17 %). 
Properties: 












1H NMR: (CDCh, 300.76 MHz) 8.74 (s, 1 H), 8.42 (d, 1 H), 7.7 (d, 1 H), 7.20 
(dd, 1 H), 4.6 (t, 2H), 4.36 (t, 2H), 4.05 (s, 5H). Good agreement 
with literature (198). 
m.p.: 58-61'C (lit: 56-58'C (199)). 
Organolithium preparation of 2-ferrocenylpyridine (2) 
This was prepared according to a literature method (200). Ferrocene (3.724 g, 
20 mmol) was added to dry diethyl ether (80 ml), under a nitrogen atmosphere. 
n-Butyllithium (20 ml of a 1.6M solution in hexane, 32 mmol) was added to this. 
This mixture was stirred, under nitrogen, for approximately four days. 
Unfortunately, due to defective equipment, this was partially exposed to 
atmospheric oxygen. Nevertheless, to this reaction mixture was added 2-
bromopyridine (1.19 ml, 12.5 mmol) in dry diethyl ether (20 ml). After overnight 
stirring, approximately 10 ml of dH20 was added, to eliminate any un reacted 
organolithium reagents. To this was added a small quantity of aqueous NaOH 
(40 %), to ensure maximum partitioning of the basic product into the organic 
phase. The organic phase was washed several times with dH20, then collected 
and solvent removed by rotary evaporation. The two major components of the 
product mixture were identified as ferrocene (R, = 0.95, in diethyl ether) and 2-
ferrocenylpyridine (R, = 0.85, in diethyl ether) by thin-layer chromatography. 
The dry product mixture was redissolved in n-hexane fractions and loaded onto 
an alumina column (MerCk, aluminium oxide 90, active neutral; deactivated by 
addition of dH20). Thin-layer chromatography revealed that only ferrocene and 
2-ferrocenylpyridine eluted in hexane. The collected hexane fractions containing 
these compounds were loaded onto a silica column (MerCk, Silica Gel 60). 











overloading of the gel. Comparatively pure 2-ferrocenylpyridine was eluted with 
diethyl ether, as confirmed by thin-layer chromatography. Solvent was removed 
under high vacuum, yielding deep red crystals (0.S22 g, 1.98 mmol, 10 %) 
Properties: 
Sticky, deep red solid at room temperature. 
Characterisation: 
1H NMR: (CDCb, 400 MHz) l5: 8.S0 (d, 1 H), 7.S7 (t, 1 H), 7.41 (d, 1 H), 7.06 
(t, 1 H), 4.92 (t, 2H), 4.40 (t, 2H), 4.0S (s, SH). Good agreement 
with literature. (201) 
Attempted preparation of (4'-methoxyphenyl)pyridine 
(Methoxyphenyl)pyridine isomers were prepared according to a literature 
method (184,202). p-Anisidine (2.470 g, 20 mmol) was dissolved in a mixture of 
water (20 ml) and concentrated hydrochloric acid (20 ml). This was cooled to 
approximately O-S'C in an ice bath, whereupon sodiu m nitrite (1.S13 g, 22 
mmol) in water (10 ml) was added, with stirring. The resulting diazonium salt 
solution was added over the course of 1S0 min to pure pyridine (4 ml, 3.92 g, 
49.6 mmol), with stirring at 70-80'C. The mixture was stirred for a further 2 h at 
80'C. The mixture was neutralised with concentrated ammonia solution and 
heated over a steam bath to allow the removal of pyridine. 
The resulting oil solution was extracted with benzene, which was removed under 
vacuum to yield the product mixture. The different product isomers were 
separated on a silica gel column with 1:1 ethyl acetate/hexane, and the 
components of each fraction determined by thin-layer chromatography. No 












Preparation of gOld(l) compounds 
Preparation of tetrahydrothiophene gold(l) chloride (3) 
This was prepared according to a well-established literature method (203). An 
aliquot of HAuCI4 stock solution (20 ml, 11.9 mmol) was added to ethanol (40 
ml). To this mixture was added liquid tetrahydrothiophene (THT), dropwise. 
Addition was continued, with stirring, until the yellow colour had faded from 
solution. The white precipitate was filtered off and washed with dH20. The 
clumpy white solid was dried under high vacuum (3.396 g, 10.6 mmol, 89 %, 
calculated from HAuCI4)' 
Properties: 
Coherent, granular white solid. Decomposes slowly to a faintly pink solid at room 
temperature, but quite stable at 4 'C. 
Characterisation: 
1H NMR (CDCIa, 300.1 MHz) l5: 3.42 (br s, 2H), 2.19 (br s, 2H). Good 
agreement with literature. (203) 
Found: 
Calc for C4HsSAuCI: 
C, 15.06%; H, 2.48%; 5,10.10%. 
C, 14.98%; H, 2.52%; 5, 10.00%. 












Preparation of Tetrahydrothiophene gold(l)pentafluorophenyl (4) 
This was prepared according to a well-established method (203). A solution of 
bromopentafluorobenzene (0.263 ml, 0.51 g, 2.06 mmol) in degassed diethyl 
ether (20 ml) at -78'C was treated with n-butyl lit hium in hexane (2.06 mmol, 
1.29 ml of 1.6 M solution). The solution was stirred for 1 h upon which a 
suspension of Au (THT)CI (0.656 g, 2.04mmol) in diethyl ether (40ml) was 
added. The colourless solution was stirred for 15 min at -78°C. The cooling 
system was allowed to warm gradually over the course of 45 min, after which it 
was removed. The mixture was then stirred for a further 2 h. Most solvent was 
then removed in vacuo to yield a white solid, with a brown substance remaining 
in solution. The solid was collected by filtration (0.5097 g, 1.13 mmol, 55 %) 
Properties: 
Fine white powder. Decomposes to a pink or purple solid, then to a brown solid, 
at room temperature, but quite stable at 4'C. 
Characterisation: 
Found: 
Calc. for C10HaFsSAu: 
C, 26.40%; H, 1.70%; S, 5.54%. 
C, 26.56%; H, 1.79%; S, 7.09%. 
m.p. Decomposes from 95-113'C 
Preparation of (3-pyridinylferrocene)AuCI (6) 
This was prepared according to the method of Barranco et al (117). 3-
Ferrocenylpyridine (26.2 mg, 0.1 mmol) was dissolved in dichloromethane (10 
ml). (THT)AuCI (32.4 mg, 0.1 mmol) was dissolved in dichloromethane (10 ml) 











then most of the solvent removed by rotary evaporation and a large excess of 
diethyl ether added. The resulting precipitate was collected by filtration and 
washed with diethyl ether (20.4 mg, 0.04 mmol, 41 %). 
Properties: 
The product was a fine orange powder, stable in air at room temperature. 
Characterisation: 
1H NMR (CDCh. 400 MHz) 6: 8.64 (s, 1 H), 8.34 (d, 1 H), 8.96 (d, 1 H), 7.41 
(t, 1 H). 4.68 (br s, 2H), 4.51 (br s, 2H), 4.11 (br s, 5H). Good 
agreement with literature values. (117) 
Found: 
Calc. for C1sH13FeNAuCI: 
C, 35.26%; H, 2.43%; N, 2.40%. 
C, 36.35%; H, 2.65%; N, 2.83%. 
Preparation of (4-pheny/pyrldine)AuC/ (6) 
Solid 4-phenylpyridine (0.217 g, 1.398 mmol) was reacted with (THT)AuCI 
(0.103 g, 0.321 mmol) in the same way described above. (Yield: 0.095 g, 0.245 
mmol, 76 %). 
Properties: 
The product was a fine brown powder, stable in air at room temperature. It is 
soluble in polar solvents such as acetone and DMSO, but highly unstable, 
yielding a colloidal gold precipitate immediately upon dissolution. It is insoluble 
in water, but unstable in the presence of moisture. The compound is soluble in 
dichloromethane and chloroform, but decomposes over the course of hours (for 












1H NMR (CDCh, 400 MHz) <5: 8.59 (dd, 2H), 7.73 (dd. 2H), 7.68 (m, 2H), 
7.56 (m, 3H). 
Found: 
Calc. for C11HgNAuCI: 
C, 34.09%; H, 2.26%; N, 3.26%. 
C, 34.08%; H, 2.35%; N, 3.61 %. 
Preparation of (3-pheny/pyridine)AuC/ (7) 
3-Phenylpyridine (0.20 ml, 0.22 g, 1.40 mmol) was reacted with (THT)AuCI 
(0.102 g, 0.318 mmol) in the same way described above. (Yield: 0.060 g. 0.155 
mmol.49 %). 
Properties: 
The product was a fine white powder. stable in air at room temperature. It is 
soluble in polar solvents such as acetone and DMSQ, but highly unstable, 
yielding a colloidal gold precipitate immediately upon dissolution. It is insoluble 
in water, but unstable in the presence of moisture. The compound is soluble in 
dichloromethane and chloroform. but decomposes over the course of hours (for 
the former) or minutes (for the latter). 
Characterisation: 
1H NMR (CDCh, 400 MHz) <5: 8.83 (d, 1H), 8.55 (d. 1H). 8.18 (dt, 1H), 7.62 
(dd. 1 H), 7.54 (m, 5H). 
Found: 
Calc. for C11 HgNAuCI: 
C, 33.92%; H. 2.31%; N. 3.31%. 
C, 34.08%; H, 2.35%; N, 3.61 %. 











Attempted preparation of (pyridine)AuCI 
CI-AU-S0 o N .. CI-AU-{ > 
This was prepared by a modification of a literature method. (115) Sufficient 
pyridine was added to completely cover a quantity of (THT}AuCI (0.080 g, 0.250 
mmol). The resulting mixture was heated gently over a steam bath, until the 
solid was dissolved. This was heated for a further 30 min, whereupon a large 
excess of diethyl ether added. The precipitate was collected by filtration and 
washed with diethyl ether. 
Properties: 
The product is a fine white powder. which decomposes gradually in air at room 
temperature. It is soluble in polar solvents such as acetone and DMSO. but 
highly unstable, yielding a colloidal gold preCipitate immediately upon 
dissolution. It is insoluble in water, but unstable in the presence of moisture. The 
compound is soluble in dichloromethane and chloroform, but decomposes over 
the course of hours (for the former) or minutes (for the latter). 
Characterisation: 
Not performed, due to instability or insolubility in standard solvents 
Found: 
Calc. for CsHsNAuCI: 
C, 19.41%; H, 1.61%; N, 4.23%. 













Decomposition around 150'C, followed by melt ing from 220-
Preparation of (4-phenylpyridine)gold(l)pentafluorophenyl (8) 
Solid 4-phenylpyridine (0.041 g, 0.27 mmol) was added to (THT)Au(CsF5) (0.123 
g, 0.27 mmol) in dichloromethane (10 ml). The mixture was stirred for 50 
minutes, after which most of the solvent was removed by rotary evaporation and 
an excess of diethyl ether added. The resulting precipitate was collected by 
filtration and washed with minimal diethyl ether to yield a fine white powder 
(0.0670 g, 0.13 mmol, 48 %) 
Properties: 
Fluffy white powder. 
Characterisation: 
1H NMR (CDCh, 400 MHz) Z5: 8.67 (dd, 2H), 7.79 (dd, 2H), 7.70 (dd, 2H), 
7.56 (m, 3H) 
Found: 
Calc. for C17HgF5NAu: 
C, 39.24%; H, 1.73%; N, 2.17%. 
C, 39.32%; H, 1.75%; N, 2.70%. 
Preparation of (3-phenylpyridine)gold(l)pentafluorophenyl (9) 
3-phenylpyridine (0.040 ml, 0.043 g. 0.28 mmol) was added directly to 
(THT)Au(CsF5) (0.116 g, 0.257 mmol) in dichloromethane (10 ml). The mixture 
was stirred for 35 minutes, after which most of the solvent was removed by 











precipitate was collected by filtration and washed with minimal diethyl ether to 
yield a fine white powder (0.012 g, 0.024 mmol, 9 %) 
Properties: 
Fluffy white powder. 
Characterisation: 
1H NMR (CDCI3, 400 MHz) ~: 8.83 (d, 1H), 8.58 (dd, 1H), 8.14 (dt, 1H), 
7.64 (dd, 1 H), 7.51 (m, 5H) 
(CDCb, 400 MHz)~: -159.6 (d, 2F), -163.2 (m, 3F) 
Found: 
Calc. for C17H9F5NAu: 
C, 39.45%; H, 1.75%; N, 2.05%. 
C, 39.32%; H, 1.75%; N, 2.70%. 
Preparation of (2-pheny/pyridine)go/d(/)pentaf/uoropheny/ (10) 
2-phenylpyridine (0.040 ml, 0.043 g, 0.28 mmol) was added directly to 
(THT)Au(CsF5) (0.111 g, 0.25 mmol) in dichloromethane (10 ml). The mixture 
was stirred for 45 minutes, after which most of the solvent was removed by 
rotary evaporation and an excess of diethyl ether added. The resulting 
precipitate was collected by filtration and washed with minimal diethyl ether to 
yield a fine white powder (0.013 g, 0.03 mmol, 10 %) 
Properties: 
Fluffy white powder. 
Characterisation: 
1H NMR (CDCI3, 400 MHz)~: 8.76 (d, 1H), 8.03 (td, 1H), 7.91 (m, 1H), 7.73 











Calc. for C17HgFsNAu: 
C, 39.66%; H, 1.72%; N, 2.11%. 
C, 39.32%; H, 1.75%; N, 2.70%. 
Preparation of gold(lII) compounds 
Preparation of auric acid (11) 
76 
This was prepared using a literature method (204). Gold metal (5.854 g, 29.7 
mmol) was placed in freshly prepared aqua regia (HClconc: HN03Conc; 3:1) (40ml) 
and stirred at room temperature until all gold particles had dissolved. Aqua regia 
was removed by evaporation over a steam bath at 70 'C, yielding orange 
crystals of HAuCI4. These were dissolved in a small amount dH20, which was 
also evaporated. The washed crystals were dissolved in dH20 (SO ml), to be 
used as a stock solution. 
Preparation of sodium tetrachloroaurate (12) 
This was prepared using a literature method (204). Solid HAuCI4 (8.674g, 21.06 
mmol,) was redissolved in a mixture of water and ethanol (1:1) (40 ml) and solid 
NaCI (1.231g, 21.06 mmol) added directly to this, with overnight stirring. As the 
orange product was highly hydroscopic, solvent could not be entirely removed, 
even with heating under high vacuum. Therefore, the product was used to make 











Preparation of (pyridine)AuC/3 (13) 
NaAuCI4 stock solution (5 ml of 21.0 mM stock, 1.05 mmol) was added to 
distilled water (10 ml). To this was added pyridine (0.12 ml, 0.12 g, 1.5 mmol), 
with stirring. A yellow solid was observed to precipitate out gradually over the 
course of 4 h stirring at room temperature. The product was collected by 
filtration, washed with distilled water and then a small amount of diethyl ether. 
The product was recovered as a bright yellow solid (0.435 g, 1.137 mmol, 108 
%). The excess yield is most likely due to the accidental addition of too much 
tetrachloroaurate stock, resulting from measurement error. 
Properties: 
Soft yellow powder at room temperature. Air stable. 
Characterisation: 
1 H NMR (acetone-d, 400 MHz) i5: 9.13 (d, 2H), 8.43 (t, 1 H), 8.00 (t, 2H). 
Found: 
Calc. for CsHsNAuCb: 
C, 15.61; H, 1.27; N, 3.00. 
C, 15.70; H, 1.32; N, 3.66. 
m.p. Melts from 238-242'C. 
Preparation of (2-pheny/pyridine)AuC/3 (14) 
This compound was prepared according to literature (205). NaAuCI4 stock 
solution (5 ml, 1.05 mmol) was added to dH20 (15 ml). To this was added 2-
phenylpyridine (0.129 ml, 0.14 g, 0.9 mmol) in acetonitrile (15 ml). With stirring, 











This was collected by filtration and washed with dH20. The fluffy, slightly yellow 
solid was dried under vacuum (0.358 g, 0.782 mmol, 74 %). 
Properties: 
Soft yellow powder at room temperature. Air stable. 
Characterisation: 
1H NMR (acetone-d, 400 MHz) i): 9.30 (d, 1 H), 8.49 (td, 1 H), 8.10 (dd, 1 H). 
8.03 (td. 1 H), 7.91 (m. 2H). 7.69 (m, 3H). Good agreement with 
literature values. (206) 
Found: 
Calc. for C11 HgNAuCb: 
C, 28.67; H, 1.08; N, 2.04. 
C, 28.81; H. 1.98; N, 3.05. 
m.p. Melts from 170-175CC 
Preparation of (3-phenylpyridine)AuCI3 (15) 
This compound was prepared according to a literature method (207). NaAuCI4 
stock solution (10 ml of 210 mM stock, 2.1 mmol) was added to distilled water 
(10 ml). To this was added 3-phenylpyridine (0.2 ml, 0.218 g. 1.40 mmol), with 
stirring. A yellow solid was observed to precipitate out gradually over the course 
of 4 h stirring at room temperature. The product was collected by filtration, 
washed with distilled water and then a small amount of diethyl ether. The 
product was recovered as a bright yellow solid (0.546 g, 1.192 mmol. 85 %). 
Properties: 












1H NMR (DMSO-d6, 400 MHz) ~: 9.53 (d, 1 H), 9.11 (br s, 1 H), 8.77 (d, 1 H), 
8.61 (d, 1 H), 7.95 (m, 1 H), 7.90 (m, 2H), 7.54 (m, 2H). 
Found: 
Calc. for C11HgNAuCIs: 
C, 28.81; H, 1.84; N, 2.04. 
C, 28.81; H, 1.98; N, 3.05. 
m.p. Decomposes for temperatures greater than approximately 170'C. 
Decomposition characterised by formation of long filaments visible 
under light microscope. 
Preparation of (4-phenylpyridine)AuCI3 (16) 
This compound was prepared according to a literature method (208). Solid 
KAuCI4 (0.265 g, 0.70 mmol) was dissolved in dH20 (10 ml). To this was added 
4-phenylpyridine (0.074 g, 0.48 mmol) in acetonitrile (10 ml). The mixture was 
stirred for 170 min, during which time the yellow colour faded from the 
supernatant and a yellow precipitate appeared. This was collected by filtration 
and washed with dH20 and diethyl ether. Some impurities appeared in the 
product, so this was redissolved in acetone, filtered, and solvent removed under 
vacuum. The product was obtained as a fluffy, yellow solid. (0.1224 g, 0.27 
mmol, 56 %). 
Properties: 
Soft yellow powder at room temperature. Air stable. 
Characterisation: 












Calc. for C11 H9NAuCI3: 
C, 28.84; H, 2.11; N, 2.59. 
C, 28.81; H, 1.98; N, 3.05. 
m.p. Melts from 218-221 'C, accompanied by some dec omposition. 
Preparation of (2-pheny/pyridine)AuC/2 (17) 
80 
Cycloauration was accomplished by the method of Constable and Leese (209). 
2-Phenylpyridine gOld(llI) trichloride (0.230 g, 0.501 mmol) was suspended in 
aqueous acetonitrile (1:1, 40 ml) and heated under reflux for 4 hours. This 
resulted in the suspended solid becoming white and the supernatant becoming 
yellow in colour. The solid was collected by filtration and washed with dH20, 
then dried under vacuum (0.066 g, 0.15 mmol, 31 %). 
Properties: 
Soft oft-white powder at room temperature. Air stable. 
Characterisation: 
1H NMR (DMSO-d, 400 MHz) l5: 9.52 (d, 1 H), 8.38 (dd, 1 H), 7.95 (dd, 1 H), 
7.80 (dd, 1 H), 7.75 (m, 1 H), 7.46 (td, 1 H), 7.37 (td, 1 H). Good 
agreement with literature values. 
Found: 
Calc. for C11 HaNAuCI2: 
C, 29.67; H, 1.64; N, 2.80. 
C, 31.23; H, 1.91; N, 3.31. 
Preparation of complex of 3-fe"oceny/pyridine with go/d(lll) (18) 
NaAuCI4 (5 ml standard solution, 1.053 mmol) was placed in a beaker and the 











directly to the mixture, gradually, with stirring. Although the ligand did not 
dissolve, it was observed that the surface of the solid became green and a 
green precipitate slowly accumulated. 3-Pyridinylferrocene was added gradually 
until the supernatant of the mixture became colourless. The mixture was then 
suction filtered and washed with water. The collected solid was washed with 
diethyl ether to remove water and then dried under high vacuum to yield a fine 
green powder (0.522 g, 0.92 mmol, 88 %). This decomposition was very rapid in 
the presence of a metal spatula, but not in the presence of glass or plastic 
implements. 
Properties: 
The compound is a very unstable bright green powder, which tends to 
decomposes to a brown solid. The compound is insoluble in non-polar solvents, 
such as diethyl ether. Contact with polar solvents (acetone, DMSO) and 
chlorinated solvents (dichloromethane, chloroform) gives rise to rapid 
decomposition, and the resulting brown solid appears to be soluble in these 
solvents. The product undergoes slow decomposition, which is quite rapid in the 
presence of water. This decomposition is slowed considerably in suspension of 
mother liquor containing tetrachloroaurate ion. Notably, this water-mediated 
decomposition occurs very rapidly when in contact with metal, such as a 
standard laboratory spatula, necessitating the use of glass implements in 
handling the product. 
Characterisation: 
Found: 
Calc. for C30H26Fe2N2Au4C112: 
C, 20.78; H, 1.59; N, 1.04. 
C, 20.71; H, 1.51; N, 1.61. 











Preparation of complex of 2-ferrocenylpyridine with gold(lII) 
A small quantity of this compound was prepared, according to the method 
described above. 
Properties: 
Very unstable green powder, which appears to decompose to colloidal gold. 
Decomposition occurs slowly in air and rather more rapidly in aqueous 
suspension. Decomposition occurs very rapidly when in contact with metal (e.g. 
metal spatula), and in solution of polar solvents (acetone, DMSO) and 
chlorinated solvents (dichloromethane, chloroform). 
Characterisation: 
No characterisation data obtained, due to the instability of the product. 
Preparation of (1,2-diphenyl-1-pyridin-4-yl-ethanol)AuCI3 (19) 
1.2-Diphenyl-1-pyridin-4-yl-ethanol (0.136 g, 0.494 mmol) was added as a white 
powder directly to a solution of KauCI4 (0.230 g, 0.609 mmol) in water (10 ml). 
This was left to stir overnight, during which time the powder changed from white 
to yellow, and the golden colour faded from the supernatant. The solid was then 
collected by filtration and washed with diethyl ether to yield a yellow powder. 
(0.1443 g, 0.249 mmol, 51 %) 
Properties: 












(CDCI3, 400 MHz) 6: 8.67 (d, 2H), 7.65 (d, 2H), 7.50 (d, 2H), 7.40 
(m, 3H), 7.21 (m, 3H), 6.91 (m, 2H), 3.48 (t, 2H). 
13C NMR: (CDCb, 400 MHz) 6: 163.00, 149.20, 143.06, 133.50, 130.57, 
129.13, 128.64, 127.70, 126.03, 125.04, 77.42, 77.00, 76.57, 
46.91) 
Found: 
Calc. for C19H170NAuCI3: 
By contrast, the starting material: 
C, 39.38; H, 3.02; N, 1.97. 
C, 39.43; H, 2.96; N, 2.42. 
(CDCI3, 400 MHz) 6: 8.49 (d, 2H), 7.46 (dt, 2H), 7.32 (m, 5H), 7.18 
(m, 3H), 6.90 (m, 2H), 3.62 (m, 2H) 
Preparation of rhodium(l) compounds 
Preparation of p-chloro(1, 5-cyclooctadiene)rhodium(l) dimer (20) 
This was prepared according to a literature method (210,211). RhCI3 (2.005 g, 
9.581 mmol) was dissolved in a mixture of water (5 ml), ethanol (25 ml) and a 
single drop of saturated Na2C03 solution (deoxygenated by nitrogen bubbling). 
To this was added 1,5-cyclooctadiene (2.0 ml, 1.8 g, 16.3 mmol), and the 
mixture was refluxed under nitrogen. The solution was observed to become a 
deeper shade of red, and a yellow precipitate formed. After 15 h, more 1,5-
cyclooctadiene (0.5 ml, 0.45 g, 4.1 mmol) was added and the reflux continued 
for further 3Yz h. The precipitate was then collected by filtration, dissolved in 











The product was obtained as fine orange-yellow crystals (1.552 g, 3.15 mmol, 
66%). 
Properties: 
Fine orange-yellow crystals at room temperature. Air stable. 
Characterisation: 
1H NMR (CDCI3• 400 MHz) 0: 4.23 (bs. 4H). 2.50 (m. 4H), 1.75 (m. 4H). 
Good agreement with literature. (212) 
Found: 
Calc. for C16H24Rh2C12: 
C. 39.15%; H. 4.94%. 
C. 38.97%. H. 4.92%. 
m.p. Melts from 226-231 'C. (Lit: (213), 140-145'C; (90). 142-144'C) 
Preparation of (1, 5-cycloocfadiene)(pyridine )rhodium(l) chloride (21) 
This was prepared according to Raj put's method (90). I.I-Chloro(1,5-
cyclooctadiene)rhodium(l) dimer (0.116 g, 0.471 mmol monomer) was dissolved 
in dichloromethane (10 ml), to which was added neat pyridine (0.04 ml, 0.04 g, 
0.50 mmol), with stirring. The mixture was stirred for 45 min, after which the 
volume of dichloromethane was reduced under vacuum to approximately 5 ml 
and excess diethyl ether added. The resulting precipitate was collected by 
filtration and washed with diethyl ether. Bright yellow crystals were collected 
(0.066 g, 0.204 mmol, 43 %). 
Properties: 












(COCh, 400 MHz) ~; 8.70 (d, 2H), 7.65 (t, 1 H), 7.27 (t, 2H), 4.12 
(br s, 4H), 2.46 (m, 4H), 1.79 (d, 4H). Good agreement with 
literature. (87) 
Found: 
Calc. for C13H17NRhCI: 
C, 46.10%; H, 5.04%; N, 3.88%. 
C, 47.95%; H, 5.27%, N, 4.30%. 
m.p. Melts from 222-226'C. (Lit: (90), 230-233'C) 
Preparation of (1,5-cyclooctadiene)(4-phenylpyridine)rhodium(l) chloride (22) 
This was prepared as described above. ~-Chloro(1 ,5-cyclooctadiene)rhodium(l} 
dimer (0.123 g, 0.499 mmol monomer) and 4-phenylpyridine (0.080 g, 0.52 
mmol) were dissolved in dichloromethane (10 ml), and stirred for 30 min, after 
which the volume of dichloromethane was reduced under vacuum to 
approximately 5 ml and excess diethyl ether added. The resulting precipitate 
was collected by filtration and washed with diethyl ether. Bright yellow crystals 
were recovered (0.1433 g, 0.357 mmol, 72 %). 
Properties: 
Fine, bright yellow crystals at room temperature. Air stable. 
Characterisation: 
1H NMR (COCh, 400 MHz) ~: 8.76 (dd, 2H), 7.59 (m, 2H). 7.49 (m. 5H). 
4.20 (bs. 4H), 2.52 (m. 4H). 1.85 (d, 4H). Good agreement with 
literature. (90) 











C, 56.80%, H, 5.28%; N, 3.49%. 
m.p. Melts from 163-169'C. 
Preparation of (1, 5-cyclooctadiene )(2-phenylpyridine )rhodium(l) chloride (23) 
This was prepared as described above. ~-Chloro(1 ,5-cyclooctadiene)rhodium(l) 
dimer (0.168 g, 0.681 mmol monomer) and 2-phenylpyridine (0.1 ml, 0.11 g, 
0.70 mmol) were dissolved in dichloromethane (10 ml) and the mixture stirred 
for 40 min. The volume of dichloromethane was reduced under vacuum to 
approximately 5 ml and excess diethyl ether added. The resulting precipitate 
was collected by filtration and washed with diethyl ether. Bright yellow crystals 
were recovered (0.105 g, 0.26 mmol, 38 %). 
Properties: 
Fine, bright yellow crystals at room temperature. Air stable. 
Characterisation: 
1H NMR (CDCla, 400 MHz)~: 8.70 (d, 1H), 8.42 (d, 1H), 7.99 (d, 2H), 7.73 
(m, 2H), 7.47 (m, 2H), 7.23 em, 1 H), 4.23 (bs, 4H), 2.48 (bs, 4H). 
1.75 (d, 4H). 
Found: 
Calc. for C19H21NRhCI: 
C, 53.00%, H, 5.27%, N, 2.53%. 
C, 56.80%, H, 5.28%; N, 3.49%. 











Preparation of (1,5-cyclooctadiene)(3-phenylpyridine)rhodium(l) chloride (24) 
This was prepared as described above. I..I-Chloro{1,5-cycI00ctadiene)rhodium(l) 
dimer (0.141 g, 0.572 mmol monomer) and 3-phenylpyridine (0.1 ml, 0.11 g, 
0.70 mmol) were dissolved in dichloromethane (10 ml) and the mixture stirred 
for 45 min. The volume of dichloromethane was reduced under vacuum to 
approximately 5 ml and excess diethyl ether added. The resulting precipitate 
was collected by filtration and washed with diethyl ether. Bright yellow crystals 
were recovered (0.185 g, 0.460 mmol, 81 %). 
Properties: 
Fine, bright yellow crystals at room temperature. Air stable. 
Characterisation: 
1H NMR (CDCI3, 400 MHz) ~: 8.96 (d, 1 H), 8.70 (dd, 1 H), 7.87 (dt, 1 H), 
7.60-7.40 (m, 5H), 7.37 (t, 1H), 4.20 (br s, 4H), 2.50 (br s, 4H), 
1.84 (d, 4H). 
Found: 
Calc. for C19H21NRhCI: 
C, 56.82%; H, 5.34%; N, 3.34%. 
C, 56.80%, H, 5.28%; N, 3.49%. 
m.p. Melts from 150-154'C. 
Preparation of (1,5-cyclooctadiene)(3-ferrocenylpyridine)rhodium(l) chloride (25) 
This was prepared as described above. I..I-Chloro(1,5-cyclooctadiene)rhodium(l) 
dimer (0.025 g, 0.1 mmol) and 3-ferrocenylpyridine (0.029 g, 0.1 mmol) were 
dissolved in dichloromethane (10 ml) and the mixture stirred for 40 min. The 
volume of dichloromethane was reduced under vacuum to approximately 5 ml 











filtration and washed with diethyl ether. Bright red crystals were recovered 
(0.021 g, 0.04 mmol, 40 %). 
Properties: 
Bright red crystals at room temperature. Air stable. 
Characterisation: 
1H NMR (COCh, 400 MHz) ~: B.BO (d, 1 H), B.52 (d, 1 H), B.71 (dt, 1 H), 7.20 
(dd, 1 H), 4.67 (t, 2H), 4.41 (t, 2H), 4.0B (s, 5H), 2.52 (br s, 4H), 
1.B5 (d, 4H), 1.55 (br s, 4H). Good agreement with literature. (59) 
Found: 
Calc. for C23H2sFeNRhCI: 
C, 54.09%; H, 4.92%; N, 2.56%. 
C, 54.26%; H, 4.95%; N, 2.75%. 
m.p. Melts from 159-163'C. 
Attempted preparation of (1,5-cyclooctadiene)(2-ferrocenylpyridine)rhodium(l) 
chloride 
IJ-Chloro(1 ,5-cyclooctadiene)rhodium(l) dimer (0.025 g, 0.1 mmol monomer) and 
2-ferrocenylpyridine (0.031 g, 0.1 mmol) were dissolved in dichloromethane (20 
ml) and the mixture stirred for 50 min. The volume of dichloromethane was then 
reduced to approximately 5 ml under vacuum and excess diethyl ether added. 
The resulting precipitate was collected by filtration and washed with diethyl 
ether. Bright red crystals were recovered (0.017 g, 0.03 mmol, 33 %). 
Properties: 











1H NMR (CDCI3, 400 MHz) z): too many signals for clear peak-picking. 
Found: 
Calc. for C23H2sFeNRhCI: 
C, 53.19%; H, 5.27%; N, 2.55%. 
C, 54.26%; H, 4.95%; N, 2.75%. 
89 
m.p: Decomposes above approximately 130'C. Melts from 161-168'C. 
Attempted preparation of chlorobis(cyc/ooctene)rhodium(l)dimer (26) 
This was prepared according to a literature method (193). Rhodium trichloride 
trihydrate (2.153 g, 8.176 mmol) was dissolved in a 40: 10 mix of isopropanol 
and dH20 (50 ml), previously deoxygenated by bubbling nitrogen gas. To this 
was added cyclooctene (6.00 ml, 5.08 g, 46.06 mmol). The mixture was stirred 
under nitrogen for 15 min, then sealed and allowed to stir for a further 7 days at 
room temperature. The resulting solid was collected by vacuum filtration, 
washed with ethanol, and dried under vacuum. The product (2.5 g, 6.97 mmol 
monomer, 85 %) was stored at 5'C under nitrogen. 
Properties: 
Bright yellow/orange powder. 
Characterisation: 
1H NMR Insoluble in all suitable solvents. 
Found: 
Calc. for C32Hs2Rh2C12: 
C, 52.48%; H, 7.03%. 
C, 53.56%; H, 7.81%. 











Attempted preparation of chloro(cyclooctene)(pyridine)rhodium(l) 
This was prepared according to a modification of the method suggested by 
Dorta et al (194,195). (Chlorobis(cyciooctene)rhodium(l) (0.1956 g, 0.545 mmol 
monomer) was suspended in toluene (10 ml). To this was added pyridine (0.07 
ml, 0.069 g, 0.87 mmol). The mixture is stirred for 270 min, after which the solid 
is collected by filtration and washed with diethyl ether. (0.1985 g, 0.453 mmol, 
83 %) 
Properties: 
Deep orange powder. Stable in air. 
Characterisation: 
(CDCI3, 400 MHz)~: 8.90 (br s), 7.53 (m), 5.31 (m), 2.16 (s), 1.76 
(br s). 
Found: 
Calc. for C21H33NRhCI: 
C, 46.60%; H, 4.17%; N, 4.27%. 
C, 57.59%; H, 7.61 %; N, 3.20%. 
Attempted preparation of chloro(cyclooctene)(4-phenylpyridine)rhodium(l) 
Chlorobis(cyciooctene)rhodium(l) (0.240 g, 0.669 mmol monomer) was 
suspended in toluene (10 ml). To this was added 4-phenylpyridine (0.1484 g, 
0.96 mmol) in toluene (5 ml). The mixture was stirred for 255 min, after which 
the solid was collected by filtration, washed with toluene, and then with diethyl 












Pale brown powder. Stable in air. 
Characterisation: 
(CDCb, 400 MHz)~: 9.02 (s), 8.82 (s), 7.79 (s), 7.42 (m), 5.64 {m}, 
2.16 (br s), 1.63 (br s). 
Found: 
Calc. for C27H37NRhCI: 
C, 33.39%; H, 3.95%; N, 5.69%. 










Chapter 3. Cytotoxicity and mechanism of action of precious metal 
complexes 




Preliminary screening of precious metal-containing compounds was carried out 
against WCH01 cells, using the crystal violet assay, described below. The 
crystal violet test provides a rapid measure of cell proliferation by staining 
proteins in cells adhering to the culture dish. A limitation of this assay is that 
dead cells that remain attached to the culture dish, and other debris, may also 
yield positive results. Conversely, this assay will fail to detect still-living cells that 
have lifted from the dish, as occurs during mitosis. The other test used to 
determine cell proliferation was the MTT assay, wherein the staining compound 
produces a quantifiable colour change when metabolised in the mitochondria of 
living cells. This gives a more accurate estimate of cell number than the crystal 
violet assay, assuming that mitochondrial quantity and function remain 
reasonably consistent between cells under different treatment regimes. The less 
accurate crystal violet assay is used here with the sole intention of identifying 
which of the panel of compounds warranted special investigation. 
The compounds tested included one gold(l) starting material (3); one gold(lIl) 
starting material (12); three phenylpyridine derivatives of gold(lIl) (13, 14, 17); 
one rhodium(l) starting material (20); three phenylpyridine derivatives of 
rhodium(l) (22, 23, 24); and cisplatin, as a positive control. Phenylpyridine 
complexes of gold(l) chloride were excluded because of their noted instability 
(particularly in DMSO, the solvent in which most treatment solutions are 
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Figure 35, A: Preliminary SCf8enlng of several metal-containll1O compounds. 
determined uslrog the crystal violet assay. Each dale pom! represents the result 
of 3 replicates. with the BIfOf bars indicatmg standard deVla!lOn. B : A table of the 











it was found that only two displayed significant anticancer activity: 3, and 12, in 
addition to the positive control cisplatin. This result was disappointing, since the 
two compounds are well-known starting materials that have already been 
thoroughly characterised. 
Evidence for the decomposition of rhodium(l) compounds 
It is interesting to note that none of the rhodium-based complexes (20, 22, 23, 
24) displayed any significant activity. 22 had already been described as 
cytotoxic in earlier studies in our research group (88) and the other compounds 
are also reasonably similar analogues of this complex, thus making it surprising 
that no activity was observed. One consideration that may account for the 
observed discrepancy is that the results depicted above correspond to 
compounds dissolved in DMSO immediately prior to use; whereas these earlier 
studies were carried out using stock solutions of compound in DMSO, which 
may have been stored for some days prior to use. From this, we may 
hypothesise that the discrepancy is due to decomposition of these compounds 
in DMSO to yield more biologically potent species. Therefore, although the 
crystal violet experiment yielding these results was performed only once, it was 
decided to prioritise testing this hypothesis, via a comparison of the activity of 
freshly-prepared solutions with those of solutions that had been kept at room 
temperature for approximately 14 days. This was performed using the more 
reliable MIT ECso assay. 
From Figure 36, A-B, it should be clear that the gold(l) compound 3 decreases in 
activity after being left in DMSO, as naive expectation would predict. This is 
presumably associated with some decomposition reactions and, indeed, a 
preCipitate is observed to come out of solution on a time scale of the order of 
days. In contrast (Figure 36, C-D), freshly-prepared 22 gives an ECso value too 
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Figure 36. Comparison of cytotoxic activity between a gOld(l) compound (3) and 
a rhodium(l) compound (22). Each compound has either been freshly made up 
in DMSO (A, compound 3; C and E, compound 22) or been allowed to stand in 
DMSO at room temperature (8, compound 3; 0 and F. compound 22). The 
vertical axis of each plot depicts an absorbance reading directly proportional to 
cell viability. Vertical error bars represent the standard deviation due to variation 
between replicates of each data pOint. The horizontal axis gives concentration in 
jJM, depicted logarithmically. A - 0 depict the results for the WHC01 
(oesophageal cancer) cell line; and E - F show results from the EPC2 (normal 











treatments used (1-100 IJM), while "old" 22 gives a EC50 value 8.3 IJM, about half 
that determined for cisplatin under the same conditions (15.0 IJM). This seems 
to confirm the hypothesis that the cytotoxicity attributed to 22 in earlier studies 
is, in fact, due to its breakdown product in DM50. It should also be noted that 
"old" 22 gives reasonably high cytotoxicity in both the cancer cell line (WHC01) 
and the relatively normal cell line (EPC2, Figure 36, E-F), which does not lead 
one to infer that the compound kills cancer cells selectively. Nevertheless, it was 
decided that the breakdown product or other chemical species responsible for 
this cytotoxic activity should be identified. 
Isolation of active rhodium(l) compound 
Characterisation of decomposition process 
This increase in activity of 22 over time is possibly associated with the 
displacement of one or other of the ligands on the complex with a DM50 
molecule. This is plausible, given the reactions of DM50 with this type of 
rhodium centre observed in the literature (see Figure 34). 
~
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Figure 37. Reaction of DM50 with chloro(1,5-cyclooctadiene)rhodium(l) dimer, 











Indeed, a solution of 22 in DMSO is observed to change from bright yellow to 
deep orange over the course of several days. Since electronic transitions in the 
rhodium(l) metal centre are responsible for the distinctive colours of these 
compounds, a change in colour would seem to indicate that some chemical 
reaction has taken place involving the metal centre. This process was monitored 
more rigorously by UV-Visible spectroscopy, depicted in Figure 38. From these 
results, several pOints are clear. Firstly, both 20 and 22 have characteristic 
peaks at 390 nm. The peak intensity for the dimer is exactly double that for 22 
which, since the former has two moles of rhodium for each mole of compound, 
confirms that this peak is primarily due to the metal centre. Secondly, 
decomposition qualitatively appears to be associated with a decline in the 
intensity of this peak. Thirdly, it appears that the decomposition process is 
substantially complete after six days, since there is no substantial difference 
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Figure 38. Decomposition of starting material 20 (A) and phenylpyridine-
containing product 22 (8) dimer, monitored via UV-visible spectroscopy 
This decomposition may also be monitored in situ via NMR in deuterated 
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Figur. 39. DeccmposilJon of 22 in deulerated DMSO, carried oul In snu In an 
NMR lube and monitored via ' H NMR. New peaks are marked by 3f1'OWS 
One very noticeable discrepancy between these oata and the results for the UV-
visible e~perimenl Is thaI chemical changes appear to take place on a much 
longer time scale. For Instance. whereas the UV-vislhle spectroscopy appears \0 











seems to indicate that distinct changes in the chemical environment of the 
aromatic ligand are still occurring at the end of the experiment on day 16. 
Several factors may account for this discrepancy. Firstly, the NMR experiment 
was carried out in a super-saturated solution of 22 in deuterated DMSO. This 
done in the hope that a larger quantity of 22 available for reaction with DMSO 
would result observable changes in the residual signals associated standard 
protonated DMSO. (As it happens, no such changes were observed, and the 
relevant region is not shown in Figure 39.) This means that unreacted solid 22 
remained in the bottom of the tube in which the experiment was conducted, 
providing a continuous source of ''fresh'' compound. Secondly, it is possible that, 
because UV-visible spectroscopy records the total or resultant colour changes in 
solution, naive use of this technique may give an inaccurate picture of a system 
where several chemical reactions are occurring simultaneously. The colour 
changes observed in Figure 38 might, for instance, only correspond to the 
formation of the species associated with peaks at 8.49, 8.03, 7.98, and 7.91 
ppm. Finally, it should be noted that the deuterated forms of various compounds 
are known to react slightly more slowly than their protonated equivalents, 
although this effect is small and unlikely to have a substantial impact here. 
Isolation of breakdown products 
The breakdown products of the decomposition of 22 were separated by means 
of partition across an aqueous/organic interface. A solution of the product in 
DMSO that had been allowed some time to decompose was mixed with a large 
excess of both toluene and water, and the various products allowed to partition 
into either phase over time. A SUbstantial portion of the product was found to be 
soluble in neither phase, forming a flocculate on the phase interface. This 
material was collected to give the product 27. 1H NMR revealed the toluene 
fraction appeared to contain starting material (data not shown). The water 











solvent. This represents something of a disappointment, as one would expect 
the water soluble fraction to be most mobile in physiological medium and thus 
most biologically active. Nevertheless, the isolated flocculate was characterised 
by NMR (Figure 40) and elemental analysis. 
The 'H NMR spectrum of 27 reveals some interesting features. It possesses 
non-solvent peaks that do not match any seen in the starting material (marked 
with. arrows in Figure 40). One notable absence is any peak corresponding to 
1 ,5-cyclooctadiene (expected at 4.12, 2.46 or 1.79 ppm), Indicating that this 
ligand has been totally displaced from this product. Peaks corresponding to the 
N-donor ligand 4-phenylpyridine are present (at 8.82, 7.65, 7.49 ppm), indicating 
that this ligand has not been displaced. Each of this peaks has been somewhat 
shifted, however, demonstrating that the chemical environment in this 
decomposition product is different to that of compound 22. The signal at 8.61 
ppm is not obviously related to any seen for 22, but may be a rhodium satellite 
peak. Particularly remarkable is the appearance of a very broad peak at 3.30 
ppm, which is characteristic of DMSO bound to a metal centre via sulfur (195). 
However, if we compare this spectrum with that obtained for the in situ NMR 
experiment (Figure 39, above), we must conclude that 27 is not the major 
breakdown product. The aromatic peaks at 8.82 and 8.61 ppm appear to 
correspond to the smaller peaks that appear only late in the decomposition 
process. The early decompoSition products corresponding to the peaks at 8.49, 
8.03,7.98, and 7.91 ppm are not visible. The DMSO peak observed in Figure 40 
is not evident as the experiment is conducted in deuterated DMSO, meaning 
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Figure 40. 'H NMR spectrum of 27. Several peaks a.e evident in the aroma~c 
region , as expected. The absence of signals in the alkene region Indicates that 
cydooctadiene has been displaced; whereas Ihe broad pea~ around 3.30 ppm 15 
characteristic 01 DMSQ coordinated via sulfur. 
Dorta el al (215) have previously atlempled Ihe reaction or excess OMSD with 
lJ-chloro(I,5-cydooctadiene)rl1odium(l) dlmer, without success (Figure 41). 
However, the data from Figure 38 clearly suggest that some reaction does occur 
over time. Furthermore, these aulhol"s note Ihat an NMR spectrum of the 
reaction solution (in deuterated iolvens) reveals very broad signals for Ihe 
alkene protons of 1,5-cyciooctadIBne, indicating rapid and temporary bindIng 01 
OMSO to the comple~ . The same authors (195,216) have prepared several 
compounds via reaclion 01 e)(cess OMSO with chlorobls(cyclooctene)rhodlum(l ) 
and ,Is derivatj~es. In these expenments, OMSO tends to d isplace \I1e 
cyclOCX: lene ligands, resuiling in a square planar complex wilh three OMSO and 
one chloride ligand. Th iS suggesls that the Increased stability of chela~ng 















Figure 41. Attempted reaction of DMSO with rhodium(l) and iridium(l) chloro-
bridged 1 ,5-cyclooctadiene dimmers (217) 
Perhaps the greatly increased concentration (as opposed to simple 
stochiometric excess) of incoming ligand resulting from dissolution in DMSO 
allows some portion of dimer to be broken down into a DMSO-containing 
monomer as suggested by Figure 41. This process would be favoured by a shift 
in the reaction equilibrium due to the increased concentration, and by the very 
long reaction time. Unfortunately, in this work, the emphasis was on exploring 
those compounds with promising biological activity, and so characterisation data 
for the breakdown product of the dimer 20 have not been collected. 
On the basis of these characterisation data and knowledge of the literature 
mentioned above, we might attempt to hypothesise a structure for 27. Firstly, the 
NMR spectrum in Figure 40 implies that both 4-phenylpyridine and DMSO are 
present in the product and, as mentioned above, 1 ,5-cyclooctadiene appears to 
be absent. This indicates that the alkene groups around the metal centre have 
been replaced by DMSO, as Dorta et al (218) have observed with 
cyclooctadiene compounds. If we assume that this is the only structural change, 
we obtain the structure depicted in Figure 42. Elemental analysis confirms that 
both nitrogen and sulfur are present, confirming that the ligands mentioned 
above are found in the complex. However, the overall analysis does not entirely 
support the hypothesised structure, giving lower-than-predicted values for 
nitrogen (1.39 %, expecting 3.11 %) and sulfur (3.22 %, expecting 7.13 











suggests that some portion of cyclooctene-containing starting material (or 
reaction intermediate) might be present in the product. 
• 
27 
Figure 42. Proposed structure for the breakdown product of compound 22 in 
rhodium 
ECso Determination 
Creation of a cisplatin-resistant cell line 
The WHC01 cell line is commonly employed within our group for screening of 
potential anti-tumour compounds (219). In order to assess the degree of cross-
resistance between cisplatin and the novel compounds described above, a 
cisplatin-resistant variant of WHC01 cell line was created. A portion of these 
cells were exposed to prolonged low concentration cisplatin treatment 
(approximately a third of the EC5o, for several weeks), so as to produce a 
cisplatin-resistant population, denoted WCH01-CR. The EC50 of both WHC01-
CR and the parent WHC01 cell line with respect to cisplatin was determined 
(Figure 43). For the parent line, the EC50 was recorded as 15 IJM (95% 
confidence interval: 8 - 29 IJM); whereas that for the putative resistant line was 
28 IJM (95% confidence interval: 15 - 52 IJM). This indicates that there is 
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Figure 43. Comparison of cisplatin efficacy against parent WCH01 cell line (A) 
versus putative resistant line (8). This figure is a representative sample from 
several replicates (see Table 1, below). 
Characterisation of cytotoxic activity 
The compounds selected for more rigorous ECso screening were chosen 
according to several criteria. Firstly, the gOld(l) chloride complexes were 
excluded because of their instability in water and DMSO, as discussed above. 
Secondly, starting materials were not included, on the grounds that they are 
well-known compounds, and so their properties are likely to be characterised 
already. Thirdly, all of the novel rhodium(l) complexes were eliminated, since 22 
was felt to be an adequate representative for these, and because it is the best-
characterised of them. It seems plausible that the decomposition products of 
these novel complexes display similar cytotoxic activity as that for 22, given the 
similarity in their structures, and the fact that these also appear to change colour 












Cisplatin was included as a control, and to determine whether the putative 
cisplatin-resistant cell line did indeed display reduced sensitivity to this drug (see 
discussion above). Both freshly prepared and decomposed 22 were tested, to 
confirm the difference in activity between the two. The rhodium starting material 
20, both fresh and decomposed, was included to ascertain whether the activity 
observed for 22 was due simply to the metal centre, or whether the 
phenylpyridine ligand was also relevant to cytotoxic activity. 27 was screened to 
give an indication whether it did indeed represent the active component (or one 
of the active components) in the decomposition mixture of 22. 14 was included 
as a representative of the gOld(lII) compounds. Since the stable 
pentafluorophenyl salts of gOld(l) only became available after the completion of 
the screening assay described above, it was decided to include compound 8 as 
a representative of this family. Finally, 4-phenylpyridine was added to ensure 
that any activity observed for a given compound was due to the complex as a 
whole, not simply the organic ligand. Testing was carried out, in the first 
instance, against WCH01, WHC01-CR and EPC2. 
The most important constraint on this experiment was that WHC01 and EPC2 
cells are only able to grow in different media. WHC01 cells are normally 
cultured in serum-supplemented DMEM, which is an extremely protein-rich 
medium. In contrast, EPC2 cells are normally grown in minimally supplemented 
(i.e. serum-free) KSFM medium. This may mean there is a lower "effective 
concentration" of treatment compound in the serum-containing medium, 
because treatment compound tends to be sequestered by proteins in the serum 
and therefore not available to exert cytotoxiC effect upon cells. Ideally, this effect 
could be eliminated by culturing the two cell lines in the same medium. 
Unfortunately, however, WHC01 does not thrive in KSFM, nor does EPC2 in 
DMEM. As a compromise, it was decided to grow the WHC01 cells in OptiMEM 
for the duration of the EC50 determination experiments. OptiMEM is a defined 
medium, containing far lower concentrations of growth factor and other proteins 











in OptiMEM results in WHC01 cells growing very slowly in comparison to their 
normal behaviour (and, indeed, to the EPC2 cells). Since induction of cell death 
by cisplatin is, to a certain extent, dependent on cells attempting to progress 
rapidly through the cell cycle (see discussion of cisplatin mechanisms of action 
above), it is possible that the unusually slow-growing WHC01 cells are 
disproportionately resistant to cisplatin under experimental conditions. Thus one 
confounding factor (the lower effective concentration of compound in 
supplemented medium) may have been swapped for another (the slower growth 
of WHC01 in serum-free medium). 
As noted earlier, and repeated here, those treatment compounds that were 
effective against WHC01 were also effective against EPC2, meaning that they 
were not selective in targeting malignant cells more than normal cells (see 
Figure 44). As suggested above, however, this may be because WHC01 cells 
are anomalously resistant to agents that target the cell cycle under low-serum 
conditions. Indeed, it should be noted that cisplatin also produced similar 
cytotoxic effects in both cell lines. Since cisplatin is known to be therapeutically 
effective, and to be selective in killing malignant cells at a greater rate than 
normal cells, the fact that this assay is unable to replicate this result may 
indicate that the test is not appropriate for estimating the selectivity of novel 
cytotoxic compounds. It was therefore decided not to continue using EPC2 cells 
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Figure 44. Cytotoxic effect of 22 (decomposed) (A and 8) or cisplatin (C and D) 
on WHC01 or EPC2 cells 
As suggested earlier, it appears that both the impure decomposition product of 
22 and the relatively pure 27 fraction exert cytotoxic activity (Figure 45, A and 
8). The ECso value for each of these compounds was of the same order as that 
of cisplatin under the same conditions. Thus, despite its relatively small 
contribution to the overall composition of the breakdown product, 27 can 
nevertheless be regarded as an active component of the decomposition mixture. 
While, as seen above, fresh 22 does not exert significant cytotoxic activity, it is 
interesting that neither does either fresh or decomposed rhodium starting 











unable to do so for these data sets because complete cell death was not 
achieved, even at the highest test concentration used (100 tJM). This implies 
that the biological activity is due not only to the interaction of DMSO with the 
metal centre (as is likely to be the case with any decomposition product 
isolated), but also to the pyridine-based ligand. 
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Figure 45. The cytotoxic effect of various rhodium compounds against WHC01 
cells. Decomposed 22 (A) has roughly the same activity as the purified form, 27 
(8). None of fresh 22 (C); fresh (D) or decomposed (E) 20 shows any activity 











Another interesting observation is that WHC01-CR displays greater resistance 
to the biologically active rhodium(l) compounds 22 and 27 than it does towards 
cisplatin (Figure 46), with significant cell death in evidence only at the highest 
treatment concentrations. If confirmed, this result implies that there is significant 
cross-resistance between cisplatin and the rhodium compounds, either because 
they induce cell death by the similar mechanism, or because they accumulate in 
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Figure 46 Biological activity of rhodium(l) breakdown products 22 (decomposed) 
(A) and the purified form, 27 (B) against WHC01-CR. Neither displays any 
cytotoxic activity, except at very high concentrations. 
Neither the gold(lIl) compound 14, nor the ligand 4-phenylpyridine by itself, 
display any significant cytotoxic activity, in any of the cell lines tested (Figure 
47). This confirms the result from preliminary screening that the gOld(lIl) 
complexes of the type under consideration do not appear to exert biological 
activity at reasonably attainable (Le. low) concentrations. The measured 
absence of activity for 4-phenylpyridine confirms that the free ligand is not a 
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Figure 48. Biological activity of 8, against WHC01 (A) and WHC01-CR (B) cell 
lines 
The final result is rather unexpected, given the noted instability of the pyridine-
based gold(l) complexes under discussion. 8 is found to exert remarkable 











toxicity, in fact, that a statistically valid EC50 should not be inferred from the data 
presented in Figure 48, as cells are observed to be killed by all but the lowest 
concentrations of treatment compound. A repeat of this assay, using lower 
concentrations of 8, is discussed below. 
Repeated testing of promising compounds 
On the basis of the experimental outcomes noted above, three compounds were 
deemed suitable for repeated testing, to ensure statistical validity of the stated 
results. In addition, cisplatin was tested further against WHC01 and WHC01-
CR, in order to confirm the putative cisplatin resistance of the latter. 22 and 27 
were included so as to define more clearly their respective cytotoxic activities 
relative to cisplatin and one another. As discussed above, the very potent 
activity of 8 stood in need of confirmation, specifically using lower concentrations 
to ensure better validity for the statistical calculation of EC50. The results for 
these calculations are depicted in Table 1, below. 
Table 1. Calculation of EC50 values for WHC01 and WHC01-CR cells with 
several promiSing compounds. 































detecting binding to DNA (221.222). Since the rhodlum{l) centre of 22 IS 
chemically simllar 10 cisplalln. II might be expected also \0 Interact with DNA, 
which would be detectable by similar means. Under Ihe eKperimenla1 protocol , a 
treatment compound IS allowed to Interact with plasmid DNA In solution, and any 
reaction Is made evident by a noticeable shift In the mobility of Ihe plasmid, due 
1.11 1 
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Figure 49. An agarose gel shOWIng purified plasmid extracts. Lane M 1: a 
standard commercial marker where Ihe successive bands are approximately 1.0 
kilobases apart: lane M2 ,I.-phage DNA digested by the Hindlll restriction 
enzyme Molecular weights for Ihe mar1<.ers are shown down the sides of the 
ftgure Lanes 1-5' individuill plasmid preparations. The origmal colours 01 the 











Several conclusions may be drawn from these data. Firstly, it seems that there 
remains a statistically significant difference in cisplatin cytotoxicity between 
WHC01 and the putatively cisplatin resistant line WHC01-CR. Several assays 
using 22 or 27 were performed against WHC01-CR, but yielded plots similar to 
those depicted in Figure 46 and for which no numerical ECso could be 
calculated. These experiments were therefore not cited in Table 1, but it should 
be noted that the earlier suggestion that these cells have developed cross-
resistance against these compounds appears thus to be confirmed. Secondly, it 
appears that both 22 and 27 do display cytotoxic activity comparable to that of 
cisplatin under these experimental conditions. 27 appears to be less active, 
although this observation should not be considered reliable until the experiment 
has been repeated on a greater number of occasions and the statistical 
uncertainties thereby reduced. 
Thirdly, it appears that 8 does, indeed, display quite considerable cytotoxicity, 
with an EC50 two orders of magnitude lower than that for cisplatin. In addition to 
this being a novel compound, it is also the first pentafluorophenyl-containing 
compound of gold(l) reported to possess cytotoxic activity. It is also one of very 
few gold(l) compounds containing a pyridine-based moiety reported to be 
biologically active, although (pyridine)gold(l) chloride has also been 
characterised (220). 
DNA Binding assays 
Gel-shift assay 
From the screening assays above, it is known that 22 (after some decompOSition 
in DMSO) is active against cancer cells in vitro. It was decided to explore its 
mechanism of action more fully. One of the common techniques for elucidating 











to topological changes induced by the chemical interaction. A readily available 
plasmid was chosen for this purpose - the pcDNA3.1 vector from Invitrogen -
and purified by standard techniques (see the experimental section of this 
chapter). The results of this purification are shown in Figure 49. 
The pure plasmid corresponding to lane 2 in Figure 49 was chosen for mobility 
studies. To perform these studies, pure plasmid was incubated at 3Te in the 
presence of various treatment agents. As seen in Figure 50, plasmid incubated 
with the positive control, cisplatin, displays a very significant mobility shift, in line 
with· results seen in the literature. The test compound, 22 produces a mobility 
shift of about the same magnitude as cisplatin, but only at double the 
concentration. Time course experiments reveal a pattern very much in line with 
expectations; with the degree of mobility shift roughly proportional to the time of 
incubation with treatment compound (see Figure 51). However the observed 
effects in these later experiments were extremely subtle compared to the result 
shown in Figure 50, raiSing the possibility that any observed mobility shifts may 
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Figure 50. Gel mobility shift assay lor ' f'lteraClIOn of compourld 22 with plasmid 
DNA lane M' A-phage DNA digested by the HlI1dll l restnct ion el'lzyme; lanes 1 
~ plasmid incubated WIth buffer or'lly: larle 2: plasmid Incubated in 11 nm 
Clsplat,n: laoe:3 plasmid Incubated in 11 rom compour'ld 22. I,me 4 plasmid 
Incubated ,n 22 nm compour'ld 22 Each sample WiJ5 Incubated for 1 hour a! 
37'C A line has been drawn between bands correspor'l ding 10 the supercolled 
form 01 DNA in both COIltroi IMes The ongH'Ial co lours 01 the gel picture have 
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Figure 51 Mobility shill assay shoWing the interaction of 22 With plasmid DNA 
Ove!" tima; 8 representative result from two repeals 01 the e~penment . lane M. 10.-
phage DNA digested by Ihe HlI'dlli restriction erlzyme. lane 1 plasmIC! 
Incubated with buffer only (3 hour incubatIOn); lane 2 incubatIOn WIth 11 nm 
clsplaun (3 hQurs): lane 3: incubation With 110m of 22 (3 hours): lane 4. 
Incubation with 22 nm 22 (3 hours); lane 5: Incubation With 22 nm 22 (2 hours); 
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Figure 52_ Mobllity shift assay shOWIng the Interaction 01 vanous lormulaHorl!; of 
22 with plasmid DNA. Lanes 1, 5 and 8: buffer only: lane 2: Incubation with 11 
nm cisp~tin; lane 3: incubation with 11 nm 22. using 1M same dilute DMSO 
stock used to carry out the inrubations in the experiments described above 
(Figure 50 and Figure 51); ~: incubation with 11 nm 22, using a dilute Siod 
freshly made from powder (no decomposIHon); lane 6: InCUbation with dilute 11 
nm 22, using a dilute stock soludoo fresl1ly made up from concentrated stock 
solution: lane 7: incubation WIth 110 nm 22. using the concentrated stock used 











As it is already known that 22 undergoes decomposition in DMSO, and that 
secOl'ldary decamposluon products form after grealer penods In so'utiOll (see 
Figure 39 and associated discussion), i1 may be speculated thallhe decl ine In 
performance of the Ireatmel1l may have been due 10 further degradatoon of the 
compound It was therefore decided to carry out Similar e~periments to those 
depicted above using Vil rfoUS "batches· of treatment comPOllnd. The result of 
thiS Is dep.eted In Figure 52 The result of this assay was, if anything. even less 
satisfactory than the \lme course experiments. Only treatment With ten limes the 
nennal concentration of compound yielded any noticeable gel Shift, and even 
tn,s may 09 interpreted as the consequence of gel 015\Ort'0I15 
Circular dichroism assay 
As reproducibility could not be achieved for the gel shift assay, despite the 
inllially promiSing resu lts. it was decided that a different DNA binding assay 
might give more consistent resu lts. Another method employed commonly In the 
literature, Including for lhe detection of cisplat in interact ion with DNA, is drcular 
d ichro ism (223) This is a form of spectroscopy which measures the relat ive 
absorption of left-handed versus right-handed cIrcularly polarised light by a 
biomolecule (224.225) 5'l1ce mal1y biomolecules are ch iral (I.e have 
handedness), the ralalive absorpuon spectra may be qUite different and so many 
of these mOlecules have dlslincuve circular dichrOIsm Signatures. 111 adcllion to 
lhe IntrinSIC t1andedness of blokJgica l monomers, large biomolecules such as 
prote ins and DNA may also be ch lral due to secondary struclure. DNA IS chiral 
cue to Ihe helica l arrangemel1t of the nhose sugars in Its backbOl1e However. 
ainee Iheae auge", typi=lIy hove IIb:;orpt'on pe<lk3 lit wllvolength3 lower thon 
190 nm. which IS about the limit 01 most available Instrumentat ion, it IS usually 
the absorptton spectra due 10 the nitrogenous bases that are measured by 










Ihal caused b~ intercalation or chemical mo(MicallOn of bases, can be observed 
qUite rtllldity 
In the spectra shown in Figl.lre 53, the characteristJc spectrum 01 duplex DNA Is 
clearly vrsible, Including II ·positive band" With a maximum al 283 nm The 
spectrum of DNA usual ly also contains a broad "nega(JVe band" lrom 220-260 
nm However, thIS is not IIIsible Mfe because the DMSO used In !he treatment 
buffer gives more intense Signals in this regoon. Treatment With Cispla~n IIllhe 
concentratIOns applied was observed to g ive nse 10 11 docrease In the IntenSlly 
of thiS postt,Ye band (Figure 53, A) The degree 01 decrease ,n band mlen5'ly 
was greater lor the larger concentratIOn of Clsplaton, 8S might be expected 
However. no substanual difference was observed between 12 h and 24 h 
if'lCtJbalion. most hkely due \0 saturation. Novel rhodH)m compounds 22 and 27 
were also included In the same expenmenl (Figure 53, 8). II shoutd be clear that 
that treatmenl With these compounds gives flse to a decrease in band IfllenSlty, 
as With cispliUln. Ttus serves 10 confirm Ihe Il"II\lal p(IsllIve results of the gel shIft 
expenment that could not be reproduced successfully. Again, there IS no 
ot:lVious d·fference in the spectra corresponding 10 difierenllncubatlOn limes With 
the same compound, Implylflg Ihal the 12 h treatment is sufficient 10 achieve 
saturation. Both Clsplalin and 22 give nse 10 Similar alteratioos 11'1 band lnlenslly 
at the r ., 0.05 treatmen t concenlrallon. At r '" 0.25, both cisplatin and 22 give 
rose to a very plonounced decline;n signal intensity. atthough that l or 22 1s more 
markC'd However, th,s may be due 10 the fad that 22 was added to the sample 
11'1 DMSQ, and the blank controtled for only the amount of DMSO prescot In the r 
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Figure 53. CirQJlar dichroism meawrement of Clsplatin (A), 22 (decomposed) 
and 27 (8 ) interacting with pcONA3.1 plasmid. Thli concen tration and inCUbatIOn 










A decrease In tne ellipticlly of !he positive band is commonly observed In 
response to metal treatment of DNA. This is often attributed to a transi tion from 
the B~ to C-form of DNA (226-23G), for sev8fal reasons The C~nformattOO of 
DNA differs from the bener-l!;nown 6-form pnmarily In that it possesses a far less 
elltensive hydration shell and Is consequently somewhal compressed. -Mlh 
polymer length per base and lhe volume of the maJOr groo\l8 redUCed. The C-
form is also more "bghtly wourlcr. in that the tum angle between succes$l\le 
bases is greater. meaning that there are fewef bases per tum of the double heh 
as a whole. To counter ele-ctrostahc reputsion between negatively dlarged 
phosphates in the DNA backbo!'l8, trle C-conformation tends to retain more 
ca tions w~hln ~s Immediate chemicat environment (231) The B- C tranSibon 
usually occurs due to a reduction in water cooten' of the DNA, a process ttlal Is 
enhanced in a solution wIth high satt concentration, particularly if the cation Is 
lithium. (231). Two primary pieces of e\lidence suggest Ihat this tranSition is 
occurring upon clsptatln binding. The first Is the B .C transition Is accompani8d 
by a dramatic decline In circular dichrOism peak Intensity for the positl\le band 01 
the affeded DNA (see Figure 54). The second IS thai clsplatm treatment induces 
a reduction In polymer length Ihat Is measurable by electron microscopy (232) 
Another proposed mecn.anism for the observed decrease in ellipticity is localised 
denaturation - that is. partial unwinding of the double heh - caused by adduct 
formation (229.233). In con trast. increases In the ellipticity 01 the positive baM 
are attnbuted to non-denaturing distortions In the DNA secondary structure, 
caused by the bl\lalent aUachmenl 01 cisplatm to adjacent guanme bases (229) 
These sorts of adduclS are known to cause the DNA double helill to oond 
considerably (234), Which may e~mlnate Ihe base-stacking Interactions that g;~e 
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Figure 54. Circular dichroism spect ra for the S- and C-/orms of ONA Adapted 
from (231 ) 
Figure 55. Crystal structure of a cispla tin adduct al dGpG, shOWing how the 
normal geometry is bent (235) 
Most of the results above refer to expenments conducted on calf thymus DNA. 
In contrast to the plasmid ONA used in this work. Th is is flot expected to make a 
large difference to the results, however, since the ultravio let region to wh ich 
circu lar dichroism is sensitive reflects mainly base-stackmg behaviour, rather 











have carried out a reasonably comprehensive study of the effects of differing 
concentrations of cisplatin on genomic DNA from various types of bacterium, 
and salmon sperm, with consequently differing tertiary structure and base 
composition. In each case, they observed that increasing concentrations of 
cisplatin, to a maximum r-value of 0.1 or 0.125, producing increasing peak 
intensity in the positive band, followed by steadily decreasing intensity. For each 
sample, the minimum recorded intensity occurred at r = 0.4, with peak height 
distinctly less than that of unaltered DNA. (Akdi et a/ (237) note a very similar 
dose dependency on plasmid DNA, albeit using a palladium compound. It 
therefore seems plausible that the overall effect of the first few molecules of 
cisplatin to form adducts on the DNA molecule create localised distortions that 
distort nucleotide interactions in such a way as to increase the signal of the 280 
nm peak. However, as greater numbers of adducts form, large-scale distortions 
of the biopolymer take place, giving rise to changes in the overall conformation 
and regions where the double helix is completely denatured. 
Macquet and Butour (236) also note that increasing cisplatin concentration 
results in a steady shift of peak location to higher wavelengths. This latter effect 
can be observed with the r = 0.25 concentration of cisplatin (Figure 53, A); but is 
not observable in treatment with the rhodium compounds, despite comparable 
decreases in band intensity. This does suggest a different mode of binding 
between cisplatin and the rhodium compounds. A further question that may be 
asked is why the metal treatments depicted in Figure 53 bring about a uniform 
decrease in band intensity, despite the fact that we might expect increased 
intensity at lower concentrations of treatment. The difference may stem from the 
buffer conditions applied. Since, according to the standard protocol, the 
rhodium treatment com pounds used in the experiments described above are 
dissolved in DMSO, DMSO was added to each of the treatment tubes requiring 
addition of these compounds. To maintain consistency, an equal quantity of 
DMSO (1% v/v) was added to each ofthe other test tubes as well. As described 











In addition, however, DMSO is known to promote denaturation of DNA by 
interfering with base pairing, and is commonly used for this purpose in 
promoting temporary denaturation in the polymerase chain reaction (238). This 
suggests that the experimental protocol inadvertently promoted denaturation, 
one of the processes by which the intenSity of the characteristic positive band of 
B-form DNA is reduced in experiments of this type. Thus, although these results 
do confirm that these compounds do interact with DNA (recall that the spectra 
representing treated DNA still differed substantially from that denoting the DNA-
only control, even though each contained equal amounts of DMSO), they do not 
give us sufficient information as to how this interaction may occur under in vivo 
conditions. 
Experimental 
Isolation of active rhodium(l) compound 
Decomposition of (1,5-cyclooctadiene)(4-phenylpyridine)rhodium(l) chloride in 
DMSO 
Compound 22 ((1 ,5-cyclooctadiene)(4-phenylpyridine)rhodium(l) chloride, 0.040 
g, 0.100 mmol) was dissolved in neat DMSO (3 ml) to give a 33.3 mM solution. 
The solution was allowed to stand at room temperature for several days. Over 
time, the solution was observed to change in colour from yellow to a deep brick 
red. These colour changes were recorded using a Varian Cary UV-Visible 
Spectrometer, using pure DMSO as a blank. 
This. decomposition was also monitored by NMR, as follows. 1,5-
cyclooctadiene)(4-phenylpyridine)rhodium(l) chloride (0.039 g, 0.098 mmol) was 











undissolved compound remaining at the bottom of the vessel. 1H NMR spectra 
were recorded over the course of several days. 
Isolation of the breakdown product of (1,5-cyclooctadiene)(4-
phenylpyridine)rhodium(l) chloride in DMSO (27) 
After the decomposition of (1,5-cyclooctadiene)(4-phenylpyridine)rhodium(l) 
chloride in OM SO was complete, as determined by UV-Visible spectroscopy, an 
aliquot of solution (2.5 ml of 33.3 mM solution) was added to toluene (20 ml) to 
produce a fine suspension. This mixture was added to H20 (15 ml), and the 
biphasic mixture was thoroughly shaken in a separating funnel. A large amount 
of flocculate was observed to form on the interface between the two phases. 
This· was separated from the toluene layer by successive washes with water. 
The flocculate was collected from the aqueous phase by filtration, and recovered 
from the filter by washing with dichloromethane. Solvent was then removed in 
vacuo to yield a deep red solid (0.004 g, 9 ~mol, 11 %). Yield calculated for 
C1sH21 N02S2RhCI. 
Properties: 
Fine, deep red powder. 
Characterisation: 
1H NMR (COCIa, 400 MHz) l>: 8.83 (br s, 2H), 7.65 (d, 2H), 7.48 (br s, 5H). 
3.23 (br s) 
Found: 
Calc. for C1sH21N02S2RhCI: 
m.p.: None recorded. 
C, 44.79; H, 4.72; N, 1.39; S, 3.22. 













Two cell lines were used. WHC01 is derived from a biopsy of a South African 
patient with malignant squamous cell oesophageal carcinoma (239), and EPC2 
is derived from healthy squamous epithelial cells of the oesophagus, which have 
been immortalised via transfection with the hTERT gene (240). All cells were 
cultured in a humidified atmosphere at 37'C with 5% CO2• WHC01 cells were 
grown either in Dulbecco's Modified Eagle Medium (DMEM), supplemented with 
10% foetal bovine serum and with penicillin (100 Ulml) and streptomycin (100 
jJg/ml); or in OptiMEM (Invitrogen), without any additional supplementation, but 
with penicillin (100 Ulml) and streptomycin (100 jJg/ml). These cells were 
normally grown in supplemented DMEM, and crystal violet assays were carried 
out in this medium. For the EC50 determinations shown above, WHC01 cells 
were transferred into OptiMEM. EPC2 cells were grown in defined K-SFM 
(Gibco), supplemented with bovine pituitary extract (40 jJg/ml), EGF (1.0 ng/ml), 
penicillin (100 Ulml) and streptomycin (100 jJg/ml). 
Passaging of cells 
Both cell types were passaged as follows. Cells were covered with a minimal 
layer of trypsin solution. After cells began to visibly lift from the dish, they were 
gently suspended by repeated aspiration and expulsion of the trypsin solution. 
For cells cultured in OptiMEM or KSFM, an equal volume of soybean trypsin 
inhibitor solution (Sigma; 0.25 mg/ml) was added to neutralise the trypsin; 
whereas for cells cultured in supplement DMEM, an equal volume of culture 











resuspended in culture medium, counted using a haemocytometer if necessary, 
and plated into a new culture dish. 
Freezing and thawing of cells 
To freeze, each cell line was grown to confluence in a 100mm culture dish. The 
cells were then trypsinised as described above, collected by centrifugation, 
resuspended in culture medium and counted using a haemocytometer. The 
cells were again collected by centrifugation and resuspended in freezing 
medium at a concentration of 1 million cells per millilitre. For WHC01 cells, this 
freezing medium consisted of complete cell culture medium (90 % v/v) and 
DMSO (10 % volume). For EPC2 cells, freezing medium consisted of foetal 
bovine serum (90 % v/v) and DMSO (10 % volume). The cells in freezing 
medium were aliquotted into plastic cryogenic tubes (1 ml per tube) and then 
frozen in a -80ce refrigerator. After freezing, cells were transferred to liquid 
nitrogen for storage. 
To thaw cells, a tube was suspended in a 37ce water bath for 1 minute. The 
freezing medium containing the cells was added to a test tube and diluted 9:1 
with the culture medium appropriate for that cell line (although just-thawed 
WHC01 cells did not grow successfully in OptiMEM). The cells were then 
collected by centrifugation, resuspended in culture medium and seeded into a 
culture dish. 
Creation of cisplatin-f9sistant line 
This' was carried out along the same lines as previously reported (241). WHC01 
cells were cultured in a 60 mm dish in supplemented DMEM, in the presence of 
cisplatin (6.68 IJM). The cells were monitored carefully for signs of cell death, 











passages of approximately three days each), the cells were judged to be in 
danger of permanent loss of viability. They were then transferred into cisplatin-
free supplemented DMEM to "recover". The cells were now monitored for the 
return of normal morphology and growth, whereupon they were returned to 
cisplatin treatment (usually after one passage of approximately five days). The 
cells were thus faced with several stringent selection events for cisplatin. After 
five rounds of selection, these cells were maintained in the same way as 
unaltered WHC01 cells for use in experiments. 
Cytotoxicity screening 
For each screening assay, cells were seeded in 90 IJI culture medium at a 
density of 3000 cells in each well of a standard 96-well plate. WHC01 cells were 
transferred from their normal supplemented DMEM growth medium into 
OptiMEM. Treatment compounds were made up in medium at the desired 
concentration and then added to the wells in 10 IJI medium 24 h after seeding. 
The final concentration of DMSO never exceeded 0.4 % in treatment culture, 
and had no impact on cell growth at this concentration. The cells were allowed 
to grow in the presence of compound for 48 h. 
The crystal violet assay was performed as follows. Medium was decanted from 
the 96-well plate and the cells fixed for 10 min in 100 % methanol. The methanol 
was poured off and 1 % w/v crystal violet solution in 1:1 methanol:water solution 
added. The cells were allowed to stain for 20 min, after which the staining 
solution was decanted and the cells rinsed with water. The crystal violet stain 
was solubilised in 1:1 glacial acetic acid:water. Plates were then read at 595 nm 











The MIT Cell Proliferation Kit (Roche) was used as per the manufacturer's 
instructions. Briefly, 10 IJI of MIT (10 mg/ml in PBS) was added to cells after 
treatment. The reaction was allowed to proceed for 4 hand 100 IJI of 
solubilisation buffer (10 % SOS in 0.01 M HCI) added. After overnight 
solubilisation at 37'C, the plates were read at 595 nm. All data points were 
carried out in triplicate. Data were analysed and ECso values calculated using 
Prism 4.03 software (Graphpad Software, Inc). The ECso value refers to the 
concentration of compound required to produce a reduction in cell number of 50 
%. Average values and confidence intervals ECso were calculated with Microsoft 
Excel, using a modification of the statistical technique suggested by the 
manufacturers of the Prism software (242). 
DNA Binding Assays 
Plasmid DNA extraction 
Plasmid DNA was extracted from a culture of XL 1-Bluescript strain of 
Escherichia coli containing the pcONA3.1 plasmid (Invitrogen), the starter 
culture being kindly provided by Caryn Buchanan. 
Briefly, a bacterial culture was grown overnight (00600 reaching 1.3) in Luria 
Broth (1 % w/v tryptone, 0.5 % w/v yeast extract, 0.5 % w/v NaCl, 1 mM NaOH). 
Cells were harvested from 1.5 ml of each culture by centrifugation (4000 rpm, 5 
min).. DNA was then extracted by one of two ways. The Peqlab E.Z.N.A.® 
Plasmid Miniprep Kit (Peqlab Biotechnologie GmbH, Erlangen. Germany) was 
used, as per the manufacturer's instructions. Alternatively, the cells were 
resuspended in 0.2 ml resuspension buffer (1 % w/v glucose in TE (25 mM Tris-
HCI, 50 mM EOTA, pH 8.0». 0.4 ml of denaturation buffer (0.2 M NaOH, 25 % 
w/v SOS) was added and the solution placed on ice for 5 min. 0.3 ml of 











added to each sample. The resulting precipitate of cellular debris was removed 
by centrifugation (12000 rpm, 10 min) and the supernatant recovered. 
Isopropanol (0.6 volumes) was then added to each sample, which was mixed 
and left for 10 min at room temperature. DNA was collected by centrifugation 
(12000 rpm, 10 min) and the supematant discarded. The pellet was washed in 
80 % ethanol and recollected by centrifugation. The supernatant was discarded 
and the pellet air-dried. DNA from each sample was resuspended in either TE or 
distilled water (0.2 ml). 
Agarose gel mobility shift assay 
The DNA binding assay uses the method of Lippard et al (243). To prepare a 
sample for a DNA binding assay, DNA (11-11, 0.3 I-Ig) was placed in an eppendorf 
tube. To this was added dH20 (3 1-11), followed by treatment compound diluted to 
the appropriate concentration in dH20 (1 1-11). The reaction volume was collected 
in the bottom of the tube by brief centrifugation, and the tube incubated in a 
water bath at 37'C for the appropriate amount of ti me. Each tube was 
centrifuged briefly at hourly intervals to ensure liquid remained concentrated in 
the bottom of the tube. After the incubation period was complete, loading buffer 
(1 1-11, 30 % glycerol in saturated bromophenol blue solution) was added to each 
tube 
The DNA solutions were electrophoresed on a 1 % agarose gel at 100 V (-7 
V/cm) for 105 min, using TBE buffer (90 mM Tris, 90 mM boric acid, 2.2 mM 
EDTA, pH 8.4). After electrophoresis, the gel was stained in ethidium bromide 
(0.001 % w/v), rinsed in dH20 with shaking, and visualised under ultraviolet light. 











Plasmid DNA in distilled water was added to further distilled water to make up 
volume for spectrometry, with final DNA concentration in the range 0.05 - 0.2 
IJg/lJgl. To this was added either cisplatin in 0.15 M saline (1.67 mM solution, 
Pharmachemie (pty) Ltd) or rhodium-containing test compound in DMSO (3.3 
mM solution). The molar concentration of DNA bases was calculated using 330 
g/mol bases, and the desired amount of treatment compound added 
accordingly. The overall concentration of both NaCI and DMSO was kept 
constant across all experimental samples. Each sample was incubated at 37'C 
for the desired time period, and analysed by circular dichroism at this 
temperature. Spectrometry was carried out using a Jasco 810 











Chapter 4. Conclusion and Future Work 
Chemistry 
In this work, novel pyridine-based complexes of gold(I), gold(lII) and rhodium(l) 
have been prepared. Despite the very challenging problem of instability with N-
donor complexes of gold(l), several pure isomers of (phenylpyridine)gold(l) 
chloride have been prepared. Unfortunately, the 2-phenylpyridine isomer was 
never isolated in pure form, and so this remains a challenge for the future. (2-
Ferrocenylpyridine)gold(l) chloride was also not isolated, despite the relative of 
stability of the 3-isomer compared to the phenylpyridines. This remains largely a 
function of the small amount of ferrocenylpyridine available and the consequent 
small scale on which experiments were conducted. In future, it may be possible 
to prepared larger quantities of all ferrocenylpyridine isomers via reaction of 
lithiated ferrocene with a large excess of pyridine (244) All three isomers of 
(phenylpyridine)(pentafluorophenyl)gold(l) have also been prepared in moderate 
yield and good purity. The yields for these complexes could most likely be 
improved by simple alterations to preparative methodology (see discussion, 
above) 
Stable phenyl pyridine complexes of gold(lII) have been prepared via a simple 
method. The equivalent ferrocenylpyridine complexes remain something of a 
puzzle, however. -rhese compounds are extremely unstable, greatly limiting the 
scope for characterisation. Nevertheless, the data that have been acquired 
suggest that complexation induces the formation of a chloro-bridged gold dimer. 
If this hypothesis is confirmed, this complex would appear to represent the first-
ever dimer of this sort containing a neutral organic ligand. The 2-











unattainable via the techniques used for the equivalent 2-phenylpyridine 
aurocycle, since the relevant intermediate is so unstable. However, the same 
target may be attained via reaction of lithiated 2-ferrrocenylpyridine (245) directly 






Figure 56. Possible route for preparation of C,N-donor 2-ferrocenylpyridine 
aurocycle 
Several derivatives of the lJ-chloro(1,5-cycI00ctadiene)rhodium(l) dimer 
containing pyridyl ligands have been prepared. via established methods. These 
compounds were found to be generally stable in air in the solid state and in 
solution, although their decomposition in DMSO has been described. Although 
the analogous starting material, chlorobis(cyclooctene)rhodium(I), has been 
prepared successfully, pure pyridine-based complexes derived 'from this have 
been elusive. This may be accounted for by the greater lability of the starting 
material, possibly leading to displacement of the cyclooctene ligands. More 
successful syntheses may be achieved in future by greater control over reaction 
conditions, including stochiometry and time of reaction. 
Although the decomposition product of 22 that has been isolated is interesting, 
not least in respect of its biological activity, it seems safe to conclude that the 
decomposition process has not been fully characterised. The identity of the 
initial decomposition product, corresponding to the 1H NMR signals appearing 











is unclear which product or products exert the major biological effect, both with 
respect to cytotoxicity and DNA binding. The use of a "standard solution" that 
may be altering in chemical composition between experiments is clearly less 
than ideal, as it leads to experimental inconsistency. Indeed, it is very possibly 
this effect that resulted in the lack of reproducibility across gel shift experiments 
(and in contrast to the consistency of the cisplatin positive control). 
It seems fair to conclude that the experimental methodology attained in 
producing the active rhodium compound is seriously flawed from the view of 
reproducibility. In future work, it would be profitable, firstly, to make better use of 
more labile cyclooctene complexes of rhodium(l) so that reactions with DMSO 
(and other ligands) would occur on a more manageable time scale. The 
products of these reactions might then be better controlled by standard 
techniques, such as stochiometry, temperature and reaction time. Indeed, the 
aim of this would be to prepare the active compound(s) by a series planned 
reactions, rather than as the result of poorly controlled decomposition. 
Biology 
Several complexes of gold(I), gOld(llI) and rhodium(l) have been assessed for 
biological activity. Of the gold(l) compounds prepared, those containing chloride 
counter-anions are too unstable in DMSO and (presumably) physiological 
medium to be effectively tested for biological efficacy. In contrast, those with a 
pentafluorophenyl counter-anion are sufficiently stable in solution to allow for 
cytotoxicity testing. Indeed, of the complexes investigated here, compound 8 
was found to have the lowest EC50. Although time limitations disallowed a 
detailed study of this compound and its isomers prepared here, it might very well 
be profitable in future to carry out more detailed biological characterisation of 
these compounds. This should include EC50 studies including a lower range of 











interesting would be certain mechanistic studies, as both the different chemistry 
and the much lower ECso indicate that this compound exerts activity via a 
different mechanism to cisplatin. Phosphine derivatives of gOld(l) are thought to 
exert activity via mitochondrial pathways (123), so various assays on 
mitochondrial function would be a good starting pOint, if only to distinguish this 
compound from these other complexes of gold(I). 
C6FS AU-\ ) ( ) 
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Figure 57. Biologically important compounds investigated in this study. An 
extremely active compound of gold(l) (8); an inactive compound of rhodium(l) 
(22), and a proposed structure for its more active breakdown product (27). 
Preliminary screening revealed that none of a representative sample of the 
gold(lll) compounds prepared showed significant cytotoxic activity. Moreover. 
despite previously reported results showing promising activity (88). none of the 
rhodium(l) complexes tested were found to be active in screening assays. It was 
hypothesised. and then confirmed. that this discrepancy is due to the breakdown 
of these complexes in DMSO. A representative compound (22) was selected for 
further study. It was determined that the activity of its breakdown product (27). in 
both "raw" and purified form, was comparable to that of cisplatin in the WHC01 
cell line. Interestingly. a variant of this cell line only slightly resistant to cisplatin 











resistance suggests that this product exerts cytotoxicity via mechanisms similar 
to cisplatin. 
Since cisplatin is known to exert activity via binding to DNA, it was decided to 
determine whether this active product also underwent these sorts of interactions. 
Some interaction with DNA was indicated by the results of gel shift experiments. 
These results, however, were not suffiCiently reproducible to draw any 
conclusions. The more sophisticated circular dichroism protocol, however, did 
confirm that some interaction was taking place. In future work, this protocol 
could be improved in several ways to yield more informative results. Firstly, 
effort should be made to eliminate DMSO from the buffer mixture, as this has its 
own effect on the conformation of DNA. Thus, while the compounds tested do 
show genuine interaction with DNA, the nature of this interaction might be 
substantially different to that which takes place under normal physiological 
conditions. Secondly, these experiments should be repeated over a broader 
range of concentrations, so as to show progressive alterations in DNA 
conformation as more compound binds. Thirdly, some effort should be made to 
find a time scale on which binding can be observed progressively (Le. before 
saturation), allowing for some understanding of the kinetics of interaction. 
There are several other assays that could usefully applied to elucidating the 
mechanism of action of the cytotoxic gold(l) and rhodium(l) compounds 
investigated here. One is the flow cytometric cell cycle assay described in 
Chapter 1, for ascertaining the effects of drugs on the cell cycle. This would 
other further comparisons between these compounds and cisplatin, since the 
latter has been characterised extensively by this technique. The cell cycle assay 
gives some idea of the proportion of cells undergoing apoptosis, in terms of the 
size of the sub-G1 population. More direct assays, however, detect the apoptotic 
protease caspase-3 directly, by making use of fluorogenic substrates of this 











these compounds are exerting cytotoxic effect. Finally, it may be useful to 
determine what signalling pathways can be implicated in initiating cell death. 
Since many cancer cell lines are p53 negative (double-mutant), it should be 
possible to compare the efficacy of these compounds in matched p53-positive or 
negative cell lines. This will help ascertain whether the mechanism of cell death 
is p53-dependent or independent. Conversely, protein-blotting experiments 
would help ascertain the effect of compound treatment on growth signalling 
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